@@@PCR °Ë»ç¿Í ºñ±³ÇØ (¿¡½ºµð¹ÙÀÌ¿À¼¾¼)½Å¼ÓÇ׿ø°Ë»ç
ÀÇ ¹Î°¨µµ´Â 17.5%,(µÎ ÁÙ·Î ¶Ñ·ÇÀÌ ³ªÅ¸³ª´Â ¾ç¼º¾ç¼ºÆÇ´ÜÀ²...Áï, À§À½¼ºÀ²82.5%....°ËÃâÀÌ ¾ÈµÇ´Â °æ¿ì°¡ ´õ ¸¹´Ù.) ƯÀ̵µ(À½¼ºÀ½¼ºÆÇ´ÜÀ²100% = À§À½¼ºÀÌ Á¦·Î...Áï, µÎÁÙÀÌ ¾È ³ª¿À¸é ÁøÂ¥ À½¼º...¹Ý´ë·Î µÎÁÙÀÌ ¶Ñ·ÇÀÌ ³ª¿À¸é ÁøÂ¥ ¾ç¼ºÀ̶ó´Â ¶æ) 100%·Î ³ªÅ¸³µ´Ù....¹Î°¨µµ´Â °Ë»çÀÚ Áß ¾ç¼ºÀ» ¾ó¸¶³ª Àß Ã£´ÂÁö¸¦ ³ªÅ¸³»´Â ºñÀ²ÀÌ°í, ƯÀ̵µ´Â À½¼º ȯÀÚ¸¦ À½¼ºÀ¸·Î Àß ÆÇÁ¤ÇÏ´ÂÁö¸¦ ÃøÁ¤ÇÏ´Â ºñÀ². ƯÀ̵µ°¡ 100%¸é Äڷγª19°¡ ¾Æ´Ñ »ç¶÷À» À߸ø Áö¸ñÇÒ È®·üÀº °ÅÀÇ ¾øÁö¸¸ ¾ç¼º°ËÃâÀ² 17%·Î ¹Î°¨µµ°¡ ³·Àº °Ô ¹®Á¦... 10¸í ȯÀÚ Áß 8¸íÀ» ³õÄ¡´Â °æ¿ì°¡ »ý±ä´Ù´Â ÀǹÌ.
[°Ë»ö : È®ÁøȯÀÚ Á¢ÃË]...[°³ÀÎÀÇ¿ø Á÷¿ø Äڷγª ¾ç¼ºÆÇÁ¤]
¿ÜºÎ±â°ü¿ë(¹ýÀÎ,±â°ü_µî)_´ëÀÀ_½Ã³ª¸®¿À_±×¸²ÆÇ(°³·«µµ)_2Â÷.pdf
**[[Á÷¿øÁß COVID19¾ç¼ºÀÚ ¹ß»ýÇÑ °æ¿ì¿¡¼ ..... ÀÚ°¡°Ý¸®±â°£¾øÀÌ ¹æ¿ª Á¾·áÇÏ´Â Á¶°Ç]]
---- ÀÚ°¡°Ý¸® ÁøÇà ¾øÀÌ (PCRÀ½¼º1ȸ½Ã) ÀÏ»ó»ýÈ°·ÎÀÇ º¹±Í°¡ °¡´ÉÇÑ Á¶°Çµé 4°¡Áö :
1> Æò¼Ò Á¾ÀÏ KF94¸¶½ºÅ© Âø¿ë ¹× öÀúÇÑ ¼Õ¾Ä±â/¹®°í¸®³ª ¼ÕÀâÀÌ ¼Òµ¶ µî ¿¹¹æ¼öÄ¢ Áؼö öÀú
2> ÃÑ ´ë»ó ÀοøÁß Àû¾îµµ 3/4´Â ´Éµ¿Àû ¹é½ÅÁ¢Á¾ 1ȸ ¿Ï·á
3> ¾ç¼ºÆÇÁ¤ÀÚÀÇ ¹ÐÁ¢Á¢ÃËÀÚ¸¦ Æ÷ÇÔÇÑ, ³ª¸ÓÁö Á÷¿øµé ¸ðµÎ PCR°Ë»ç»ó À½¼º ÆÇÁ¤
4> ¹é½Å1ȸÁ¶Â÷µµ (¾î¶°ÇÑ ÀÌÀ¯·ÎµçÁö) ¸ÂÁö ¸øÇÑ Á÷¿øÀÌ ÀÖ´Ù ÇÏ´õ¶óµµ °ÅÁÖ °ø°£ÀÌ ¾ç»óÆÇÁ¤ÀڷκÎÅÍ ¶³¾îÁ® ÀÖ°í È°µ¿³»¿ëÀÌ ¼·Î ´Þ¶ó¼ ¹ÐÁ¢Á¢ÃË ¹ß»ý °¡´É¼ºÀÌ °ÅÀÇ ¾ø´Â °æ¿ì
-myIVTvc10. VD-se-fe.aa51.pppsam.ala300a.
-Dry AMD !! : tumebrom + ActN-ZnSeVD
--COVID19°¨¿°ÀÇ º´ÀÎ..^IFN-1°¨¼Ò=NOX2»ó½Â/ACE2»ó½Â/nrf2ÀúÇÏ ^TGFbeta»ó½Â/TLR4»ó½Â ^STINGÀå¾Ö(IFN-1Áö¿¬, °ú´Ù»ý»ê)--->> **ACTn-tume/brom-ART-ZnSeD
When Hepatitis B Virus Meets Interferons - NCBI
>>2020.09.09 ¹Ð°¡·ç ¸ø ¸Ô´Â ‘¼¿¸®¾Çº´’, ´Ù¸¥ ¼Òȱâ Áúȯ°ú È¥µ¿Çϱ⠽¬¿ö
Ưº°ÇÑ ÀÌÀ¯ ¾øÀÌ º¹ºÎ Æظ¸°¨°ú ¼³»ç, º¹ÅëÀ» °Þ´Â´Ù¸é °ú¹Î¼º ´ëÀå ÁõÈıºÀ̳ª ¼ÒȺҷ®À̶ó°í »ý°¢Çϱ⠽±´Ù. ÇÏÁö¸¸ ÀÌ´Â ¹Ð¿¡ ÇÔÀ¯µÈ ±Û·çÅÙÀ» ¼·ÃëÇÒ ¼ö ¾ø´Â ‘¼¿¸®¾Çº´’ÀÇ ÇÑ Áõ»óÀÏ ¼ö ÀÖ´Ù.
¼¿¸®¾Çº´Àº ±Û·çÅÙ ¼·Ãë·Î ÀÎÇØ ¼ÒÀå¿¡ ¼Õ»óÀ» ÀÔ´Â À¯ÀüÀû ¼ÒÀÎÀÌ ÀÖ´Â »ç¶÷µé¿¡°Ô ¹ß»ýÇÏ´Â ½É°¢ÇÑ ÀÚ°¡ ¸é¿ª Áúȯ Áß Çϳª´Ù. ¼¿¸®¾Çº´ ȯÀÚµéÀº ¸é¿ª°è°¡ ¹Ð, È£¹Ð, º¸¸®¿¡ Æ÷ÇÔµÈ ±Û·çÅÙ¿¡ ´ëÇÑ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ» º¸À̹ǷΠÆò»ý ±Û·çÅÙÀÌ ¾ø´Â ½Ä»ç¸¦ ÇØ¾ß ÇÑ´Ù.
Áõ»óÀ» ¹æÄ¡ÇÒ °æ¿ì ½Åü °÷°÷¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°°í Èí¼öÀå¾Ö·Î ÀÎÇÑ °ñ´Ù°øÁõ, ÇǺιßÁø, Ä¡¾Æ ¹ý¶ûÁú °áÇÔ, ¼ºÀåÁö¿¬, °üÀýÅë, »çÃá±âÁö¿¬, À¯»ê, ºÒÀÓ µîÀÌ º´¹ßÇÒ ¼ö ÀÖ´Ù.
NIH¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â 141¸í Áß 1¸íÀÌ ¼¿¸®¾Çº´À» ¾Î°í Àִµ¥, ´Ù¸¥ ¼Òȱâ ÁúȯÀ¸·Î ¿ÀÀÎÇÏ°í Áõ»óÀ» ¹æÄ¡ÇÏ´Â °æ¿ìµµ ÀûÁö ¾Ê´Ù. Celiac Disease Foundation¿¡¼´Â ¾à 250¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¼¿¸®¾Ç º´¿¡ ´ëÇØ Áø´Ü¹ÞÁö ¸øÇÏ°í ÀÖÀ¸¸ç ÀÌ·Î ÀÎÇÑ ½É°¢ÇÑ °Ç° ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù°í ¸»ÇÑ´Ù.
¼¿¸®¾Çº´ÀÌ ¹ÐÀ» ÁÖ½ÄÀ¸·Î ¼·ÃëÇÏ´Â ¼¾çÀε鿡°Ô ÈçÇÑ ÁúȯÀ̶ó°í »ý°¢Çϱ⠽±Áö¸¸, ÀÌ´Â µ¿¾ç¿¡¼ ¼¿¸®¾Çº´¿¡ ´ëÇÑ ¿¬±¸°¡ Àû±ØÀûÀ¸·Î ÀÌ·ïÁöÁö ¾Ê¾Ò±â ¶§¹®ÀÌ´Ù.
ƯÈ÷ ½ÒÀÌ ÁÖ½ÄÀÎ ¹®È±Ç¿¡¼´Â ±Û·çÅÙ ¼·Ãë°¡ ºó¹øÇÏÁö ¾Ê°í ±×¸¸Å Áõ»óÀÌ µå¹°±â ¶§¹®¿¡ ¿Ã¹Ù¸¥ °Ë»ç¿Í Áø´ÜÀÌ ÀÌ·ç¾îÁö´Â µ¥ ÇÑ°è°¡ ÀÖ´Ù.
¼¿¸®¾Çº´ÀÇ ÁÖµÈ Â¡ÈÄ
- ¼³»ç - º¹ºÎ Æظ¸°¨ - °úµµÇÑ °¡½º - ¸¸¼º ÇÇ·Î - üÁß °¨¼Ò - öºÐ °áÇ̼º ºóÇ÷ - º¯ºñ
- ¿ì¿ïÁõ - ÇǺο°, ½ÀÁø, °Ç¼±, ÇǺΠ¹ßÁø
¼¿¸®¾Çº´ÀÌ ÀÖ´Â »ç¶÷µé ´ëºÎºÐÀº °ú¹Î¼º´ëÀåÁõÈıºÀ̶ó´Â Áø´ÜÀ» ¹Þ°í »ì¾Æ°£´Ù. Áõ»óÀÌ ºñ½ÁÇϱ⠶§¹®Àε¥ Áø´Ü ¿¬·ÉÀÌ ´Ê¾îÁú¼ö·Ï ¶Ç ´Ù¸¥ ÀÚ°¡¸é¿ª ÁúȯÀÌ µ¿¹ÝµÉ ¼ö ÀÖ¾î ºü¸¥ Áø´ÜÀÌ Áß¿äÇÏ´Ù.
°ú¹Î¼º´ëÀåÁõÈıº¿¡ ´ëÇÑ ¾àÀ» º¹¿ëÇÏ°í ½Ä½À°üÀ» ¹Ù²å´Âµ¥µµ ³ª¾ÆÁöÁö ¾Ê´Â´Ù¸é Áõ»ó¿¡ ´ëÇÑ ÀÚ°¡ Áø´ÜÀ» ÅëÇØ ÀÌ»ó ¿©ºÎ¸¦ È®ÀÎÇÏ°í ÀÇ·á±â°üÀ» ¹æ¹®ÇØ ±Û·çÅÙÇ×ü °Ë»ç¸¦ ½Ç½ÃÇÏ´Â °ÍÀÌ ±ÇÀåµÈ´Ù. ¶ÇÇÑ, °¡Á· ³» ¼¿¸®¾Çº´ ȯÀÚ°¡ ÀÖ´Â °æ¿ì À¯Àü °¡´É¼ºÀÌ ³ôÀ¸¹Ç·Î Áõ»óÀÌ ¾ø´õ¶óµµ °Ë»ç°¡ ÇÊ¿äÇÏ´Ù.
[[**º£¾Æ¸Æ(Æú¶óÇÁ·¹Â¡Å© 75mg/T...23%zinc+77%L-carnosineų·¹ÀÌÆ®Çü) Á¶½ÄÈÄ, ÃëħÀü..±Þ¸¸¼ºÀ§¿°/À§±Ë¾ç(37.5mgZn)]]
>>¿øÀι̻ó üÁß°¨¼Ò
¾Æ¹«¸® ¸Ô¾îµµ »ìÀÌ ÂîÁö ¾Ê´Â °ÍÀº ¸ðµÎ°¡ Èñ¸ÁÇÏ´Â »çÇ×ÀÌÁö¸¸, ½ÇÁ¦·Î ½Ä»ç·®°ú ºñ±³ÇØ »ìÀÌ ÂîÁö ¾Ê°Å³ª ¿ÀÈ÷·Á ¸ö¹«°Ô°¡ ÁÙ¾îµç´Ù¸é °Ç°ÀÇ ÀÌ»ó ½ÅÈ£ ÀÏ ¼ö ÀÖ´Ù. ¸ðµç üÁß °¨¼Ò°¡ ½É°¢ÇÑ ÁúȯÀÇ Â¡ÈÄ´Â ¾Æ´ÏÁö¸¸, Ưº°ÇÑ ³ë·ÂÀ» ÇÏÁö ¾Ê¾Ò´Âµ¥µµ 6~12°³¿ù ¾È¿¡ 5% ÀÌ»óÀÇ Ã¼ÁßÀÌ ºüÁ³´Ù¸é ½Åü¿¡¼ ³ªÅ¸³ª´Â ÀÌ»ó Áõ»óÀº ¾ø´ÂÁö È®ÀÎÇغÁ¾ß ÇÑ´Ù. ÀÌÀ¯ ¾ø´Â üÁß °¨¼Ò°¡ Áö¼ÓµÈ´Ù¸é ´ÙÀ½°ú °°Àº ÁúȯÀ» ÀǽÉÇغ¼ ¼ö ÀÖ´Ù.
°©»ó¼± ±â´É Ç×ÁøÁõ
½Åü ´ë»ç·®À» Á¶ÀýÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °©»ó¼±¿¡¼ È£¸£¸ó ºÐºñ°¡ °ú´ÙÇØÁö°Å³ª ±â´ÉÀÌ ºñÁ¤»óÀûÀ¸·Î Ç×ÁøµÈ °æ¿ì¿¡´Â ½Åü ´ë»ç°¡ ÇÊ¿ä ÀÌ»óÀ¸·Î È°¹ßÇØÁ® üÁßÀÌ °¨¼ÒÇÒ ¼ö ÀÖ´Ù. ÀÚÀ²½Å°æ ±â´ÉÀÌ ÈïºÐµÇ¾î ½É¹Ú¼ö°¡ »¡¶óÁö¹Ç·Î ½ÉÀåÁúȯÀÌ Àְųª ³ëÀε鿡°Ô´Â ºÎÁ¤¸ÆÀÌ ¹ß»ýÇÒ ¼ö ÀÖ¾î ÁÖÀÇÇØ¾ß ÇÑ´Ù. ¶ÇÇÑ ¿ ¹ß»ýÀÌ ¸¹¾ÆÁ® ´õÀ§¸¦ Ÿ¸ç, ½Å°æ°ú¹Î, ºÒ¾ÈÁõ ¹× ¾È±¸µ¹Ãú Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¾Ï
´ëºÎºÐÀÇ ¾ÏÀº ÀǽÉÇÒ¸¸ÇÑ ÀüÁ¶Áõ»óÀÌ ¾ø´Ù. ´Ü ¸î Á¾·ùÀÇ ¾ÏÀº üÁß ±Þ°¨À» µ¿¹ÝÇϴµ¥, ´ëÇ¥ÀûÀ¸·Î´Â ÃéÀå¾ÏÀÌ ÀÖ´Ù. ÃéÀå¾ÏÀº üÁß°¨¼Ò¿Í Ȳ´Þ, º¹ºÎ ÅëÁõ µîÀÌ ÁÖµÈ Áõ»óÀ¸·Î °¡Á··ÂÀÌ Àְųª ´ç´¢º´ µî °íÀ§Ç豺¿¡ ÇØ´çÇÏ´Â °æ¿ì ÁÖ±âÀûÀÎ °Ç°°ËÁøÀ» ÇØ¾ß ÇÑ´Ù. ¹Ì±¹ ¾Ï ÇÐȸ¿¡ µû¸£¸é ÃéÀåÀ» ºñ·ÔÇØ Æó, À§ ¹× ½Äµµ¾Ï¿¡¼ üÁß °¨¼Ò°¡ ÈçÇÏ°Ô ³ªÅ¸³´Ù.
´ç´¢º´
´ç´¢º´ÀÌ »ý±â¸é ½Åü°¡ Æ÷µµ´çÀ» ¿¡³ÊÁö·Î »ç¿ëÇÏÁö ¸øÇØ ¼Òº¯À¸·Î ºüÁ®³ª°¡¸ç, ÀÌ·Î ÀÎÇØ °¥Áõ°ú ´Ù´¢¸¦ ¹Ýº¹ÇÏ°Ô µÈ´Ù. ´ç´¢º´ ȯÀÚµéÀº ±ÙÀ° °¨¼Ò¸¦ µ¿¹ÝÇϱ⵵ ÇϹǷΠüÁß °¨¼Ò°¡ ÀϾ ¼ö ÀÖ´Ù.
¼¿¸®¾Çº´
±Û·çÅÙ ¼·Ãë¿¡ ´ëÇÑ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ» º¸ÀÌ´Â ÀÚ°¡¸é¿ªÁúȯÀÎ ¼¿¸®¾Çº´ÀÌ À־ üÁß °¨¼Ò¸¦ °ÞÀ» ¼ö ÀÖ´Ù. ¼¿¸®¾Çº´Àº ¹Ð, È£¹Ð, º¸¸®¿¡ Æ÷ÇÔµÈ ±Û·çÅÙ ¼·Ãë ½Ã ¼ÒÀå¿¡ ¼Õ»óÀ» ÀÔ´Â ÁúȯÀ¸·Î ¼³»ç, º¹ºÎ Æظ¸°¨, ¸¸¼ºÇǷθ¦ µ¿¹ÝÇÏ´Â Áõ»óÀ» °æÇèÇÑ´Ù. ¹æÄ¡ ½Ã ½Åü °÷°÷¿¡ ¿°Áõ ¹ÝÀÀ°ú ÇÔ²² Èí¼öÀå¾Ö¸¦ °ÞÀ» ¼ö ÀÖ´Ù.
¸¸¼º Æó¼â¼º Æó Áúȯ
õ½Ä°ú °°Àº ¸¸¼º ±â°üÁö¿°À» Æ÷ÇÔÇÑ ¸¸¼º Æó¼â¼º Æó Áúȯ(COPD)Àº ÈäºÎ ¾Ð¹Ú°ú ÇÔ²² °æ¹ÌÇÑ È£Èí °ï¶õ, °¡º¿î ±âħÀÌ ÁÖµÈ Â¡ÈÄ·Î ³ªÅ¸³´Ù. È£ÈíÀÌ Èûµé¾îÁú¼ö·Ï ½Åü´Â ´õ ¸¹Àº ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ°Ô µÇ¹Ç·Î Áõ»óÀÌ ¾ÇÈÇϸé üÁß°¨¼Ò°¡ ºü¸£°Ô ÀϾ ¼ö ÀÖ´Ù. Cleveland Clinic¿¡ µû¸£¸é ¸¸¼º Æó¼â¼º Æó ÁúȯÀÌ ÀÖ´Â »ç¶÷µéÀº È£Èí ½Ã Á¤»óÀκ¸´Ù 10¹è ¸¹Àº ¿¡³ÊÁö°¡ ÇÊ¿äÇÏ´Ù.
==========
>>Á¢ÃË·Â ¹ß¿(Ãʱâ¹Ì¿-->Á¡Â÷¾ÇÈ) È£Èí±âÁõ¼¼ ´ëºÎºÐ ¹ßÇö[°Ç±âħ->ÀÎÈÄÅë/Àü½ÅÅë(¸ö»ì, µÎÅë)->¼ûÂü/°´´ãÁõ°¡ =°·ÂÀǽÉ] + À§ÀåÁõ¼¼ 1/5¹ßÇö [½Ä¿åÀúÇÏ->±¸¿ª±¸Åä15%->º¹Åë<10%->¼³»ç =°·ÂÀǽÉ] :: È£Èí±âÁõ»ó(°í¿, °Ç±âħ, ¼ûÂü) ¾ø´Â È£Èí±â¹«Áõ»óÀÚµµ Àֱ⠶§¹®¿¡ Á¢ÃË·Â+ÀåÁõ»ó¸¸ ÀÖ´Ù¸é ÇǶó¸Æ½º+ÀÚ°¡°Ý¸®¸¸ Çصµ ÁÁÀ» °Í))
====Camostat USE=== GERD¿ë¹ý Àû¿ë¿ë·®ÀÌ¸é ¾ÈÀüÇÒ µí(ÇÏ·ç ÃÑ 2.1gmÀÌÇÏ·Î »ç¿ë½Ã)..
::: 1Á¤´ç 100mgÀ̹ǷÎ===>[±âÁØ¿ë·®] 170 mg × 2 daily in a 70‐kg human. ..ÇÏ·ç 2ȸ »ç¿ë..1ȸÃßõ¿ë·® ÃßÁ¤ °è»ê ==> 30kg :: 72mg...40Kg :: 97mg...50kg :: 121mg ...60kg: 145mg 70kg :: 170mg.....80kg :: 194 ....90kg :: 218mg
========
>>2020.09.24 [À±Èñ¿µÀÇ News English] Äڷγª19¿Í µ¶°¨ÀÇ Áõ»ó Â÷ÀÌ ±¸ºÐ¹ý
Äڷγª19¿Í µ¶°¨ÀÌ µ¿½Ã¿¡ â±ÈÇÏ´Â ½ÖµÕÀÌ ÆÒµ¥¹Í(twin pandemics), ‘Æ®À©µ¥¹Í(twindemic)’ ¿ì·Á°¡ Ä¿Áö°í ÀÖ´Ù. µÎ °¨¿°º´(infectious disease)Àº Áõ»óÀÌ ºñ½ÁÇØ Çò°¥¸±(be confused) ¼öµµ ÀÖ¾î ºÒ¾È°¨À» ´õÇÑ´Ù(aggravate anxiety).
µÑÀ» ±¸ºÐÇÒ ¼ö ÀÖ´Â(tell them apart) ¹æ¹ýÀÌ ÀÖ±â´Â ÇÏ´Ù. ¹Ì±¹ ¿ù½ºÆ®¸®Æ®Àú³Î¿¡ µû¸£¸é, ¸Å¿ì Èí»çÇÑ Áõ»óµé(remarkably similar symptoms)À» º¸À̱â´Â ÇÏÁö¸¸, ³ªÅ¸³ª´Â ¼ø¼°¡ ¾à°£ ´Ù¸£´Ù(be slightly different).
Äڷγª19´Â °í¿·Î ½ÃÀ۵ȴÙ(begin with a fever). ÀÌÈÄ ±âħ, ¿åÁö±â·±¸Åä, ¼³»ç ¼ø¼·Î ÁøÇàµÈ´Ù. ù Áõ»óÀÎ °í¿Àº ¹Ì¿·Î ½ÃÀÛÇØ(start as a low-grade fever) ½Ã°£ÀÌ Áö³ª¸é¼ ¾ÇȵÅ(get worse over time) ¿ÀÇÑÀÌ ´À²¸Áö±âµµ ÇÑ´Ù(have chills).
µÎ ¹ø° Áõ»óÀº ±âħ(cough)ÀÌ´Ù. µ¶°¨°ú ´Þ¸® ¸¶¸¥ ±âħÀÎ °æÇâÀÌ ÀÖ´Ù(tend to be dry). ÀÌ¾î¼ ÀÎÈÄ¿°(sore throat), ¸ö»ì(body ache), µÎÅë(headache) µîÀÌ µÚµû¸£±âµµ ÇÑ´Ù. ´ÙÀ½¿£ ¿åÁö±â(nausea)¿Í ±¸Åä(vomiting)°¡ ³ªÅ¸³ª±âµµ ÇÏ°í, ½Ä¿åºÎÁø(lack of appetite)°ú º¹Åë(abdominal pain) °°Àº ¼Òȱ⠰èÅë Áõ»óÀÌ À̾îÁö±âµµ ÇÑ´Ù.
°¡Àå ³ªÁß¿¡´Â ¼³»ç(diarrhea) Áõ»óÀÌ ÀϾÙ. ±×¸®°í ¹Ì°¢À̳ª ÈÄ°¢À» ÀÒ¾î¹ö¸®°Ô(lose the sense of taste or smell) µÇ´Âµ¥, ÀÌ·± Áõ»óµéÀº µ¶°¨¿¡¼´Â Á»Ã³·³ ¹ß»ýÇÏÁö ¾Ê´Â´Ù(be unlikely to occur with the flu).
µ¶°¨ Áõ»ó À¯ÇüÀº Äڷγª19¿Í °ÅÀÇ °°Áö¸¸, ÇÑ °¡Áö Áß¿äÇÑ ¿¹¿Ü(exception)°¡ ÀÖ´Ù. °í¿°ú ±âħÀ̶ó´Â ù µÎ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ø¼(order of the first two symptoms to appear)°¡ °Å²Ù·Î´Ù(be reversed). Äڷγª19´Â °í¿·Î ½ÃÀÛµÇ°í ±âħ<ƯÈ÷ °Ç±âħ> Áõ»óÀÌ µÚ¸¦ Àմµ¥ ºñÇØ µ¶°¨Àº ±âħÀÌ ¸ÕÀú ³ª¿À°í °í¿ÀÌ ³ªÁß¿¡ ¹ß»ýÇÑ´Ù.
µ¶°¨Àº ±âħ µî Áõ»óÀÌ °¨¿° ÀÌÈÄ(after being infected) 1~4ÀÏ À̳»¿¡ ±ÞÀÛ½º·´°Ô ¹ßÇöÇÏ´Â °Í°ú ´Þ¸® Äڷγª19 Áõ»óÀº °¨¿°µÇ°í 2~14ÀÏÀÌ Áö³ª¼¾ß ³ªÅ¸³´Ù. ¶Ç µ¶°¨Àº ÀÎÈÄ¿°°ú µÎÅëÀÌ ±âħ°ú °ÅÀÇ °°Àº ½Ã±â¿¡ ³ªÅ¸³ª´Âµ¥(come on about the same time), Äڷγª19¿¡¼± ÀÌ·± Áõ»óµéÀÌ °ÅÀÇ ÀϾÁö ¾Ê´Â´Ù. Ä๰(runny nose)À̳ª ÄÚ¸·Èû(nasal congestion), Àçä±â(sneezing) Çö»óÀÌ »ý±ä´Ù¸é À̰͵µ Äڷγª19°¡ ¾Æ´Ï¶ó µ¶°¨¿¡ °É¸°(come down with the influenza) Áõ»óÀ̶ó°í ÆÇ´ÜÇÏ¸é µÈ´Ù.
ÇÑ °¡Áö ºÐ¸íÇÑ °ÍÀº ¸¶½ºÅ©¸¦ ¾²°í(wear a mask), »çȸÀû °Å¸® µÎ±â¸¦ ÁؼöÇϸç(keep your social distance) ¼ÕÀ» ÀÚÁÖ ¾ÄÀ¸¸é, 3ÁßÀ¸·Î À̷οòÀ» ÁشٴÂ(provide a triple advantage) »ç½ÇÀÌ´Ù. Äڷγª19 È®»êÀ» ÁÙÀÌ°í(reduce Covid-19 spread), µ¶°¨ Àü¿° °¡´É¼ºÀ» ³·Ãâ(cut back the chances of influenza transmission) »Ó ¾Æ´Ï¶ó ÀÏ¹Ý °¨±â À§Çèµµ ¹æÁöÇÒ(ward off the risk of the common cold) ¼ö ÀÖ´Â ‘ÀÏ°Å»ïµæ(ìéËáß²Ôð)’ È¿°ú°¡ ÀÖ´Ù.
[[Áõ»óÁøÇà»óÀÇ ºñ±³]]
##COVID : *1)ùÁõ»óÀº ¹ß¿: óÀ½ ¹Ì¿·Î ½ÃÀÛ==>°í¿/¿ÀÇÑ -->*2) ´ë°³ 2-14ÀÏ°æ, ±âħ(°Ç±âħ)-ÀÎÈÄÅë-¸ö»ì-µÎÅë-->*3)±¸¿ª±¸Åä, ½Ä¿åºÎÁø-º¹Åë, ¼³»ç-->*4)¹Ì°¢/ÈÄ°¢»ó½Ç
##µ¶°¨ : *1)1-4ÀÏÀ̳» ùÁõ»óÀº ±âħ/°¡·¡ + ÀÎÈÄÅë/µÎÅë +ºñ·ç/ºñ»ö/Àçä±â --->*2)°í¿/¿ÀÇÑ
[Âü°í ¿µ¹®ÀÚ·á »çÀÌÆ®]
¢Ñ https://www.thehealthy.com/infectious-disease/covid-19-symptoms-vs-flu-symptoms/_cmp=TheHealthy&_ebid=TheHealthy9132020&_mid=368937&ehid=a18d22eb68950e7ad262b00aa03c2e0459c6e8ac
¢Ñ https://www.wsj.com/articles/flu-vs-covid-ways-to-identify-symptoms-and-differences-11600088401
¢Ñ https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
¢Ñ https://www.businessinsider.com/difference-between-coronavirus-symptoms-flu-allergies-common-cold-chart-2020-9
¢Ñ https://www.muhealth.org/our-stories/flu-cold-or-covid-19-consider-symptoms
----------
¿µÁöÃßÃâ¹°Åõ¿©½Ã antioxidant status (MDA, GSH, SOD, GPx), biochemical (ALT, AST, glucose, triglycerides, cholesterol, urea), and hematological parameters (red blood cells, white blood cells)¸ðµÎ È£Àü, ¿°Áõ/¹ß¿ ½Å¼Ó È£Àü[pro‐inflammatory cytokines (NF©§B, TNFα, IL6) ÀúÇÏ+ UCP1, SIRT1 ȸº¹]
-------------
**·çÅ׿ø°(¶¥Äá¼Ó²®Áú¼ººÐÃßÃâ¹°..¿ø·¡ ¹Ì»ö~¿¬³ë¶û~¿¬ºÐÈ«»öÀÌÁö¸¸ ±¸¿ì¸é °¥»ö)---Sirt1½ÅÈ£Àü´Þ ÃËÁøÈ°¼º, KEAP1-NRF2º¹ÇÕüºÐ¸®»ý¼ºÃËÁø-Nrf2ÇϺÎÀÇ Ç×»êȴܹéÁúµé »ó½Â(Ho-1, NQO1, SOD, GSH)//¿°Áõ¼Õ»ó°æ·Î ¹°Áúµé ÀúÇÏ(ROS, TNF-alpha, p38MAPK, p65NFkB)//Ÿ°Ù¼¼Æ÷ÀÇ ¿°Áõ ÀúÇÏ(p53ÀúÇÏ, Bcl-2»ó½Â, BAXÀúÇÏ)
----dry type age-related macular degeneration(AMD)ÀÇ Ä¡·áÀü¸Á----
AMDÀÇ 10%´Â wet type(Ȳ¹Ý³»·ÎÀÇ ºñÁ¤»óÀû Ç÷°üÁõ½ÄÀÌ Æ¯Â¡--Ç×VEGFÄ¡·áÁ¦ »ç¿ë), ±×¿¡ ¹ÝÇØ..³ª¸ÓÁö90%´Â dry type(ROS¿¡ ÀÇÇÑ ¸Á¸·»ö¼Ò»óÇÇ °á¼ÕÀÌ Æ¯Â¡).....NAC(sulfahydryl±â °ø±Þ¿ø/GSHÀü±¸Ã¼)Åõ¿©½Ã GSH¼Ò¸ð°¡ Ư¡(( + inc.NOX4 p22phox>>NOX2, NOX5))ÀÎ Retinal Pigment Epithelium-lossÇü dryAMD(age-related macular degeneration)ÀÇ ¿¹¹æ ¹× Ä¡·á °¡´É¼ºÁõ´ë!!
-----COVID19 and/or Influenza °¨¿°½Ã 1ÇüÀÎÅÍÆä·Ð Áõ»êÀÚ±ØÁ¦---------
***NOX2(NADPH Oxidase2) inhibitors = type I IFN(¾ËÆÄ, º£Å¸) inducer....[È®Á¤] ¹Ù½ºÆ¼³¿¥¾Ë(TMZ..¼öÃà·ÂÀúÇÏ+ºÎÁ¤¸Æ µ¿¹Ý+ ´ç´¢º´¼º½É±ÙÁõ>ÇãÇ÷½É±ÙÁõ¿¡ Ưȿ)/¸®Æ÷»ê(Ƽ¿ÁÆ®»ê¿¡ÀÌÄ¡¾Ë) SeZnVD-C-B3 ¾ÈÅä½Ã¾Æ´Ñ(ºí·çº£¸®Æú¸®Æä³î),º£¸£º£¸°/º£Å¸½ÃÅ佺Å×·Ñ ¼³Æ÷¶óÆÇ/Ä¿Å¥¹Î Çö󺸳ëÀ̵å(Äõ¼¼Æ¾/ÈÖ¼¼Æ¾, įÆä·Ñ, ¸ð¸°)>>[ÃßÁ¤] Ÿ³ª¹Î(Ginko Biloba), HDMPPA(¹èÃß±èÄ¡È°¼º¼ººÐ¸Þź¿ÃÃßÃâ¹°HDMPPA), ¿¡¸ðµò(´ëȲÃßÃâ¹°), ·¹½ºº£¶óÆ®·Ñ(Àû»ö¿ÍÀÎ), ½Ã³ë¸Þ´Ñ>......IFN-1Áõ»êÀÇ ½ÇÁ¦ ¿¹½Ã :: Æò¼Ò, ½ºÇǷ縮³ª15±×·¥ (¶Ç´Â picocyanobilin,PCB100mg ÇÔÀ¯ÇÑ ½ºÇǷ縮³ª ÃßÃâ¹°), Á¦2»óÇص¶È¿¼ÒÀ¯µµÁ¦ (¿¹ : Æä·ê»ê500~1000mg, ±×´ë½Å ¸®Æ÷»ê1200~1800mg ¶Ç´Â ¼³Æ÷¶óÆÇ), NAC 600mg, ¼¿·¹´½50-100mcg ¹× ¾Æ¿¬50mg ±Û·çÄÚ»ç¹Î3gÀÌ»ó ¸ÆÁÖÈ¿¸ðº£Å¸-±Û·çÄ250~500mg ¾ÈÅä½Ã¾Æ´Ñ(¿¤´õº£¸®ÃßÃâ¹° 600~1500mg)
------------
==anti-pdk1(PDK1¾ïÁ¦Á¦)Àº Ç׳ëÈ + ³ëȼ¼Æ÷(±×·Î±â»óÅÂ)ÀÇ Á¤»óÈ ¿ªÀü ÅëÇØ ¼¼Æ÷¼ö¸í¿¬Àå À¯µµ==
==Ä¿Å¥¹ÎÀº anti-PDK1È°¼º±âÀü ÅëÇØ ÀÛ¿ëÇÏ°í ÀÖÀ½!!! ==
Æ÷½ºÆÄƼµôÀ̳ë½ÃÅç3-Å°³ªÁ¦(PI3K)/Akt (=PKB, ´Ü¹éÁú Å°³ªÁ¦ B¶ó°íµµ ÇÔ) /¶óÆÄ ¸¶À̽ÅÀÇ Æ÷À¯·ùÇ¥Àû(mTOR)½ÅÈ£ ÃàÀº ½ºÆ®·¹½º ¹ÝÀÀ, ¼¼Æ÷ ¼ºÀå ¹× »ýÁ¸À» Æ÷ÇÔÇÑ ¿©·¯ Áß¿äÇÑ ¼¼Æ÷ ±â´ÉÀÇ Á¶Àý¿¡ Á᫐ ¿ªÇÒÀ» ¼öÇàÁß ... CurcuminÀº ´Ü¹éÁú Æ÷½ºÆÄŸÁ¦ ÀÇÁ¸ ¸ÞÄ¿´ÏÁòÀ» ÅëÇØ Akt / mTOR ½ÅÈ£ Àü´ÞÀ» ¾ïÁ¦ÇÔ..., Á» ´õ ¼¼¹ÐÇÏ°Ô ±â¼úÇÑ´Ù¸é, curcumin¿¡ ÀÇÇÑ Akt / mTOR ½ÅÈ£Àü´ÞÀÇ ¾ïÁ¦´Â Ä®¸®Ä𸰠A- ¹Î°¨¼º ´Ü¹éÁú Æ÷½ºÆÄŸÁ¦ ÀÇÁ¸Àû Å»ÀλêȷκÎÅÍ ¹ß»ýÇÑ´Ù´Â °ÍÀÌ ÀÔÁõµÇ¾úÀ½!!!....°á·ÐÀûÀ¸·Î °íÂûÇØ º¸¸é..phosphotidylinositol-dependent kinase-1 (PDK1) ¹× Akt´Â ¼¼Æ÷¸·¿¡ ÇÔ²² µ¿¿ø, ¹ßÇöµÇ°í Akt´Â PDK1 ¹× PDK2 (¾Æ¸¶µµ mTOR º¹ÇÕü 2)¿¡ ÀÇÇØ Thr308 ¹× Ser473 ÀܱâºÎÀ§¿¡¼ °¢°¢ ÀλêÈ°¡ ÀϾ°Ô µÈ´Ù ( 2 , 3). Àλêȸ¦ °ÅÃÄ È°¼ºÈ µÈ Akt´Â ±Û¸®ÄÚ°Õ ½Å¼¼Å¸Á¦ Å°³ªÁ¦3 (GSK3), Forkhead°è¿ Àü»çÀÎÀÚ ¹× mTOR ( 4 )¸¦ Æ÷ÇÔÇÑ °ú´ÙÇÑ ±âÁúÀ» ÀλêÈ ¹× Á¶ÀýÇÏ°í ÀÖ´Â ¹Ý¸é 10 ¹ø ¿°»öü (PTEN)¿¡¼ °á½ÇµÈ Æ÷½ºÆÄŸÁ¦¿Í ÅٽŻóµ¿Ã¼´Â PIP2¿Í PIP3¸¦ Å» ÀλêÈÇÏ¿© PI3K È°¼ºÀ» ¹æÇØÇÔÀÌ È®ÀεǾú´Ù ( 5 ). =Ä¿Å¥¹ÎÀº anti-PDK1È°¼º±âÀü ÅëÇØ ÀÛ¿ëÇÏ°í ÀÖÀ½!!!
---------
[SIRT1ÀÇ ÀÌÁßÀÛ¿ë...½ÇÇè½Ç»ó ³»Àμº±âÀüTh17=IL-17AÈ°¼ºÁõ°¡..¿ÜºÎsirt1È°¼ºÁ¦Åõ¿©½Ã´ÂTh17¾ïÁ¦] SIRT1activators :: ÀºÇàÀÙÃßÃâ¹°(GBE.Ÿ³ª¹Î) ¾ÈÅä½Ã¾Æ´Ñ/·çÅ×ÀÎ/Á¦¾Æ»êÄ£/¾Æ½ºÅ¸»êÄ£ ·¹½ºº£¶óÆ®·Ñ/Æ÷µµ¾¾ÃßÃâ¹°(GSE. vitis vinisfera.¿£Å×·Ð), Àλï/¸¶Ä«-°¨ÃÊ-¿À¹ÌÀÚ-¿µÁöÃßÃâ¹°. ½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG, Ä¿Å¥¹Î, ÆÄÀÌÆ丰, ¸ÞÆ®Æ÷¸£¹Î. Äõ¼¼Æ¾/ÈÖ¼¼Æ¾. º£Å¸½ÃÅ佺Å×·Ñ º£¸£º£¸°(¸Åȳª¹«ÃßÃâ¹°)/·çÅ׿ø°(¶¥Äá²®ÁúÃßÃâ¹°). º£Å¸±Û·çÄ. CoQ10. MSM. ºñŸ¹Î B3( ´Ï¾Æ½Å+´Ï¾Æ½Å¾Æ¹Ìµå).ºñŸ¹ÎD. DHEA+PREG, ÀÎÅÍÆä·Ð-º£Å¸ NAC(DCMP-dryAMD-µà¼¾Çü±ÙÀÌ¿µ¾çÁõ-COPD:ÇÁ¸®¾ÆÆ¿)//¸ÞÆ®Æ÷¸£¹Î(±Û¶óºñ½º¼¹æ) -->SIRT1È°¼º==>KEAP1-Nrf2È°¼º ¹× ÇϺÎÇ×»êȴܹéÁúÀ¯µµ + Th17a(=IL-17AÈ°¼º : ¼±Ãµ¸é¿ªÀÇ °¨¿°º¸È£ÀÛ¿ë ÀûÁ¤¼º Áõ´ë....SIRT1 activator´Â STAT3 deacetylationÀ» ÅëÇØ Th17ÀÇ ¿À¹ö½´ÆÃÀ» ¹«µð°Ô ÇÏ¿© ¼±Ãµ¸é¿ª+ÈÄõ¸é¿ª¹ÝÀÀÀÇ ÀûÁ¤¼ºÀ» À¯Áö½ÃÅ´)
[NRF2activators] nrf2 »ó½Â, IFN1ÀúÇÏ, NFkB ÀúÇÏÇö»óÀÌ Æ¯Â¡::½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG, Ä¿Å¥¹Î ÆÄÀÌÆ丰(ÈæÈÄÃßÃßÃâ¹°) ºê·Î¸á¸°(ÆÄÀξÖÇÃÃßÃâ¹°), È£³ëÅ°¿Ã(¸ñ·ÃÃßÃâ¹°) Ȳ±â(astragalus) HCQ. SAMe+Zn, ALA
--------------------------------------------------------------------
**SP1, specificity protein: DNA¿¡ ÀÛ¿ëÇÏ´Â Àü»çÀÎÀڷμ stress-induced NOA(non-oncogenic addiction)¿¡ ¼ÓÇÔ....³ªÀ̵é¸é¼ ¹ßÇöÀº °¨¼ÒÇÏ´Â °æÇâ.....ÇÑÆí, Á¤»ó¼¼Æ÷°¡ ¾Ï¼¼Æ÷·Î º¯ÇüµÉ ¶§ »ó½ÂÁ¶ÀýµÇ¾î , SP1, SP3, SP4´Â DNAÀÇ ¾Ï¼¼Æ÷º¯ÇüÀ» Áß°³ÇÔ......¾Ï¼¼Æ÷¼ºÀå, »ýÁ¸, À̵¿/ħ½À, ¿°Áõ ¹× ¾àÁ¦ ³»¼º°ú Á÷Á¢ °ü·ÃµÊ.(À§´ëÃéÀå¾Ï-À¯¹æÀü¸³¼±Æó¾Ï-½Å°æÁ¾¿¡¼ ¿¹Èĺҷ®ÀÎÀÚ).... SP1, SP3, SP4´Â ¿ø·¡ ÀüÇüÀûÀÎ ¾ÏÀ¯ÀüÀÚ°¡ ¾Æ´ÏÁö¸¸ ½ºÆ®·¹½º¿¡ ³ëÃâµÈ °á°ú [¿ ¹× Àú»ê¼ÒÁõ¿¡ ³ëÃâ·Î ÀÎÇÑ ´Ü¹éÁúº¯Çü½Ã heat-shock protein¹ßÇöÀ» Á¶ÀýÇÏ´Â, heat-shock response·Î ÀÎÇØ »ý¼ºµÇ´Â HSF1(heat-shock factor1)µµ ¸¶Âù°¡Áö] »ý¼ºµÇ´Â Non-oncogenic Addiction(NOA: ºñ¾ÏÀ¯ÀüÀںΰ¡ À¯Àüü)·Î¼, Ä¡·áÁ¦ Ÿ°ÙºÎÀ§·Î ¸Å¿ì Áß¿ä....Áï, ¾î¶² ½ºÆ®·¹½º°¡ ÁÖ¾îÁ³À» ¶§, curcumin, aspirin and metformin µîÀ» »ç¿ëÇϸé SP TFs¾ïÁ¦¸¦ ÅëÇØ ¾Ï¼¼Æ÷Áõ½ÄÀ» ¸·´Â chemopreventionÈ¿°ú¸¦ ¾ò°ÔµÊ..
--**NF-κB and IRF pathways: cross-regulation on target genes promoter level...crosstalk between pathways activated by RIG-I(IFN-1¹ÝÀÀÀ¯µµ) and TLR3 receptors(NFkBÈ°¼ºÀ¯µµ) in response to pathogens(¹ÙÀÌ·¯½º)...crosstalk diagram of the IRF - NF-κB pathways. ....members of the NF-κB family may directly impact regulation of IRF family, while IRF members impact regulation of NF-κB family rather indirectly, via other transcription factors such as AP-1 and SP1. =¹ÙÀÌ·¯½º°¨¿°Á÷ÈÄ IFN-1ÀÇ ÃʱâÁõ»ê¹ÝÀÀÀÌ Áö¿¬µÇ´Â ÀÌÀ¯.
---**COVID19°¨¿°½Ã º´ÀαâÀüÀÇ Æ¯Â¡Àº COVID19¿¡ ÀÇÇÑ NRF2 Â÷´Ü/ACE2 Áõ°¡, Ãʱâ IFN-I ÀúÇÏ/TGF-1beta Áõ°¡, TLR4 Áõ°¡, IFN-1ÀÇ Áö¿¬¼º °ú´ÙºÐºñ(STINGÀå¾Ö), Th17¿À¹ö½´ÆÃÀ¸·Î ÀÎÇÑ ARDS/Æó·Å-ÆÐÇ÷Áõ¼º¼ï/´Ù¹ß¼ºÀå±âºÎÀüMODS µîÀÌ Á¦ÀÏ Áß¿ä ::: Ç׸»¶ó¸®¾ÆÁ¦ÀÎ pyronaridineÀº IFN-1Áõ»êÀÛ¿ëÀÌ Àִµ¥ ¹ÝÇØ, nrf2 È°¼º±â´ÉÀÌ ÀÖ´Â HCQ/CQ/¾Æ¸£Å׹̽ôÑÀÇ ´Üµ¶Åõ¿©´Â ÀϹÝÀûÀÎ nrf2È°¼ºÁ¦µéó·³ IFN 1À» ¿©ÀüÈ÷ °¨¼Ò½ÃÅ°±â¿¡ °¨¿°Ãʱ⿡ ¹ÙÀÌ·¯½º¹Ú¸êÀÌ °ï¶õÇÑ ¹®Á¦¸¦ °¡Áö°í ÀÖÀ½ [RA/SLEȯÀÚ¿¡¼ HCQÀÇ Ä¡·áÈ¿´ÉÀº IFN I°¨¼Ò±âÀüÀ» ¿ªÀÌ¿ëÇؼ °ú´ÙÇ×ÁøµÈ ¸é¿ª½Ã½ºÅÛÀ» ÇÏÇâÁ¶ÀýÇϴµ¥¿¡ ÀÖÀ½ !!], µû¶ó¼, COVID19°¨¿°Áõ»ó ¹ßÇö½Ã¿¡´Â HCQ/¾Æ¸£Å׹̽ôѿ¡, ¾ÆÁöÆ®·Î¸¶À̽Űú ¾Æ¿¬¿¡ ´õÇÏ¿© Ãʱ⿡ IFN IÀ» Ãß°¡Åõ¿©¸¦ °í·ÁÇϰųª, sirt1È°¼ºÁ¦(Th17À» ¿ÀÈ÷·Á ÇÏÇâÁ¶ÀýÇÔ)ÀÌ¸é¼ µ¿½Ã¿¡ nrf2È°¼ºÈ¿°ú¸¦ °¡Áö°í ÀÖ´Â Æ®¸®¸ÞŸÁöµò, ºñŸ¹ÎD, B3, ¾ËÆĸ®Æ÷»ê-¾ÈÅä½Ã¾È, ¶Ç´Â Ä¿Å¥¹Î-¼³Æ÷¶óÆÇ µîÀÇ NOX2 inhibitor±â´ÉÀ» °¡Áø nrf2 activator>sirt1 activator¸¦ º´¿ëÅõ¿©ÇÏ¿© IFN-1»ó½ÂÀ» À¯µµ + COVID¹Ú¸êÇÏ¸é¼ µ¿½Ã¿¡ STINGÀå¾Ö ÇØ°á+ Th17¿À¹ö½´ÆÃÀ» Â÷´ÜÇÏ°í, ÀÌ¿¡ ´õÇÏ¿© NAC·Î TGF-1beta¸¦ Â÷´ÜÇÏ¿© local/systemic fibrosis¿Í ARDSÁøÇàÀ» Â÷´ÜÇØ Áְųª ¾Æ¿¹ ÇǶó¸Æ½º ¼±ÅÃÀ» °í·ÁÇÒ °Í....-----
^^TGF-1beta È°¼º °æ·Î : viremia-Æó¼¶À¯È/ARDS À¯¹ß °æ·Î
^^STING È°¼º °æ·Î: cGAS/STING/TBK1/IRF3 innate immunity pathway....LPS-induced TLR4 activation(inc.expression of proinflamm.cytokine such as IRF3, MAPK, NFkB) : ÆÐÇ÷Áõ¼º¼îÅ©/MODSÀ¯¹ß °æ·Î : IRF3´Â ÀÎÅÍÆä·ÐÀÇ Áö¿¬¼º °ú´ÙºÐºñ¿Í ¿¬°áµÊ.
***HCQ and (intranasal) IFR-1 for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances :: [COVID19³ëÃâÀü ¿¹¹æ¸ñÀû »ç¿ë½Ã, ¸»¶ó¸®¾Æ ¿¹¹æ½ºÄÉÁì µû¸¦ °Í...1ÁÖ°£°Ý 1ȸ 400mg½ºÄÉÁì]pre-exposure prophylaxis³ª post-exposure prophylaxis[COVID19ȯÀÚÁ¢ÃËÈÄ ¿¹¹æÀº 5ÀÏ°£ ¸ÅÀÏ 400mg-¾ÆÁöÆ®·Î¸¶À̽Å-¾Æ¿¬ 3Áß¿ä¹ý..ºñ°³» IFNÅõ¿© Ãß°¡ °í·Á]¿¡ 80%È¿°ú... --------------
[[The Role of Natural Products in Targeting Cardiovascular Diseases via Nrf2 Pathway: Novel Molecular Mechanisms and Therapeutic Approaches]]
**NRF2È°¼ºÀ¯µµÁ¦µé(phthalide, Catechin Chalcone DiarylHeptanoid) ÀÛµ¿°æ·Î¿ä¾à
A>Nrf2»ý¼ºÀ¯¸® »ó½ÂÁ¶Àý °æ·Î È°¼º(Á÷Á¢ È¿°ú) : Cul3-Rbx-E2-Ubcomplex=2Keap1=Nrf2 º¹ÇÕü»óŸ¦ p62ÀÚ±ØÇÔÀ¸·Î½á nrf2 inhibitorÀÎ keap1Àº Å»¶ôµÇ°í free Nrf2¸¸ ¼¼Æ÷Áú·Î À¯¸®µÇ¾î ³ª¿È : ÇÙ³»·Î À¯ÀԵǾî sMaf-Nrf2º¹ÇÕü ÀÌ·ç¾î Nrf2Ÿ°ÙÀ¯ÀüÀÚÀÎ ARE geneºÎÀ§¸¦ È°¼º/Àü»ç½ÃÄѼ °á±¹ Ç×»êȴܹéÁú ¹× phase II Á¦µ¶È¿¼Ò »ý»êÃËÁø :½ÉÀ庸ȣÀÛ¿ë=Çù½ÉÁõ/½É±Ù°æ»ö/³úÁ¹Áß¿¹¹æÈ¿°ú ¹ßÇö ...nrf2È°¼ºÀÇ Á÷Á¢Àû È¿°ú(¾Æ·¡¿¡ Á¤¸®ÇÔ)
1>Keap1ÀÇÁ¸°æ·Î : *Keap1ÀÇ cysteineº¯Çü *Nrf2/keap1»óÈ£ÀÛ¿ë ÇØü·Î free Nrf2À¯¸®
2>Keap1ºñÀÇÁ¸°æ·Î :*epigenetic regulation *protein kinases ÀλêÈ·Î free Nrf2À¯¸®
B>Nrf2¿Í ¿¬°üµÈ ¼¼Æ÷ °æ·Î È°¼º(°£Á¢ È¿°ú) : 1>2>3>°á°ú·Î ½É³úº¸È£ÀÛ¿ë ÃËÁø º¸Á¶
1>ROS ÀúÇÏ + ±Û·çŸġ¿Â ¼öÁØ »ó½ÂÁ¶Àý : *GRD»ó½Â(NADPH¿Í GSSG·Î ºÎÅÍ NADP+, GSH»ý¼ºÁõ°¡) *GPX»ó½Â(GSH¸¦ GSSG·Î º¯È¯ÇÏ¸é¼ °ú»êȼö¼Ò¸¦ ¹°·Î ¹Ù²Þ)
2>NFkB¿ÍÀÇ crosstalk.....NFkBÀ¯¸®/È°¼º¾ïÁ¦ = ¿°Áõ»óÅ °³¼± º¸Á¶. : *IKb-NFkBº¹ÇÕüÀÇ ºÐÇظ¦ ¾ïÁ¦ == I-kBÀÇ Å»¶ô ¹× I-kB kinase ÀλêÈ ¾ïÁ¦¸¦ ÅëÇØ.
3>foam cell Á¶Àý : ´ë½Ä¼¼Æ÷³»·Î oxLDLÀÌ À¯ÀԵǴ°ÍÀ» ¾ïÁ¦(SR-A, CD36, LOX-1¾ïÁ¦ÅëÇØ) +´ë½Ä¼¼Æ÷·ÎºÎÅÍ ÄÝ·¹½ºÅڷιæÃâÀ» ÃËÁø(ABCA1»ó½Â½ÃÄѼ ApoA1»ý»êÀ», ABCG1, SR-B1»ó½Â ÅëÇØ HDL»ý»êÀ» ÃËÁø ---Ç÷°ü¼Õ»ó ¹× µ¿¸Æ°æȺ´º¯ ¹ß»ý ¾ïÁ¦ +ÇöóÅ© ÇؼÒÃËÁø
--------------
[[Sirt1/Nrf2 signalling pathway prevents cognitive impairment in diabetic rats through anti‑oxidative stress induced by miRNA‑23b‑3p expression]]
***SIRT1 È°¼ºÀ¯µµÁ¦µéÀº Ç׿°-Ç×»êÈ-Ç׳ëÈ-¼¼Æ÷¼ö¸í¿¬Àå/ÀÚ»ì¹æÁö±â´ÉÀ» ³ªÅ¸³»¸ç, SIRT1/nrf2 ½ÅÈ£°æ·Î´Â »êȽºÆ®·¹½º ÀúÇ×±âÀü ¹× ³ú¼¼Æ÷³» miRNA-23b-3p»ó½ÂÁ¶Àý±âÀüÀ¸·Î ÇнÀ/±â¾ï µî ÀÎÁö±â´É¾Çȸ¦ ¿¹¹æÇÒ ¼ö Àֱ⿡ Ä¡¸Å/ÆÄŲ½¼º´/Àú»ê¼Ò¼º³ú¼Õ»óÀÇ ¿¹¹æ°ú Ä¡·á¿¡ À¯¸ÁÇÔ...
[[Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease]]
ÇÑÆí, SIRT1Àº °£¿¡¼ Æ÷µµ´ç, ÁöÁú, ÄÝ·¹½ºÅ×·Ñ Ç×»ó¼ºÀ» À¯ÁöÇϸç, ±× Ã˸ÅÈ°¼ºÀÌ NAD+ÀÇ ¼¼Æ÷°¡¿ë¼º¿¡ µû¶ó ´Þ¶óÁö´Â Ã˸ÅÀÌÀÚ ´ë»ç¼¾¼·Î ÀÛ¿ëÇÏ´Â classIII È÷½ºÅæ Å»¾Æ¼¼Æ¿ÈÈ¿¼Ò·Î¼, SIRT1°ú ¿°Áõ¹ÝÀÀÀÇ ¸¶½ºÅÍÁ¶ÀýÀÚÀÎ NFkB»çÀÌ¿¡´Â »óÈ£±æÇ×see-sawÁ¶Àý°ü°è¿¡ ÀÖÀ½ : NFkBµµ ¹°·Ð SIRT1À» ¾ïÁ¦ÇÒ ¼ö ÀÖÀ¸³ª (±×°á°ú NAFLD¹× °£¿° À¯¹ß) SIRT1Àº NFkbÀÇ p65 ¼ºêÀ¯´ÖÀ» Å»¾Æ¼¼Æ¿ÈÇÏ¿© ¼¼Æ÷ÇÙÀ¸·ÎºÎÅÍ NFkB¸¦ Á¦°ÅÇϱ⿡ SIRT1È°¼ºÀ¯µµÁ¦µéÀº NAFLD µî Áö¹æ°£ ¹× °£¿° ¹× ¸é¿ª/¿°ÁõÁúȯġ·áÁ¦·Î¼µµ ¸Å¿ì Áß¿äÇÔ..
[[The systemic role of SIRT1 in exercise mediated adaptation]]
>¼¼Æ÷¿¡³ÊÁö¿ä±¸·®Àº ½Åü ¿îµ¿ Áß¿¡ ½±°Ô º¯°æµÇ¾î NAD+ ÀÇÁ¸¼º ¶óÀ̽Šµ¥¾Æ¼¼Æ¿¶óÁ¦ SIRT1À» Æ÷ÇÔÇÑ ´ë»ç °úÁ¤ÀÇ ´Ü¹éÁú ½ÅÈ£¸¦ ÅëÇØ ÀûÀÀ¹ÝÀÀÀ» ÀÏÀ¸Å´...±ÔÄ¢ÀûÀÎ ¿îµ¿Àº ½Å°æÅðÇ༺Áúȯ ȯÀÚÀÇ ½ÅÀå, °£, ³ú¿¡¼ SIRT1 ¼öÁØÀ» ȸº¹½ÃÅ°´Â Àü½ÅÀû ÀûÀÀÀ» À¯¹ßÇÔÀ¸·Î½á ¼¼Æ÷´ë»ç°úÁ¤À» Á¤»óÈÇÏ°í ÀÌ·¯ÇÑ Áúº´ÀÇ ÁßÁõµµ¸¦ ¾àȽÃÅ´....°ñ°Ý±Ù¿¡¼ SIRT1ÀÇ °ú¹ßÇöÀº ±ÙÇÙÀÇ ¼ö¸¦ Áõ°¡½ÃÄÑ ±Ù°ñ°Ý°èÀÇ ºÎ»óÈÄ È¸º¹°úÁ¤À» °³¼±ÇÔ°ú ´õºÒ¾î µ¿ÈÀÛ¿ëÀ» »óÇâÁ¶ÀýÇÏ°í ÀÌÈÀÛ¿ë °úÁ¤À» ÇÏÇâÁ¶ÀýÇÏ¿© ±ÙÀ° ºñ´ë¿¡ Àû±ØÀûÀ¸·Î °ü¿©ÇÔ
>¾×ƾ¿¡ ¹Ì¿À½Å Á߼⸦ ºÎÂøÇÒ ¶§¸¶´Ù ¸ðµç ºÎÂø°úÁ¤¿¡´Â ATP°¡ ÇÊ¿äÇϱ⠶§¹®¿¡, °í°µµ¿îµ¿Àº °ñ°Ý±ÙÀ¸·Î ÇÏ¿©±Ý ±×¿¡ ÇÕ´çÇÑ ÃæºÐÇÑ ¾çÀÇ ATP¸¦ »ý»êÇϵµ·Ï ¿ä±¸ÇÏ°Ô µÊ....ÀÌ ATP»ý¼º¿¡´Â ¹ÌÅäÄܵ帮¾Æ ÀüÀÚ Àü´Þ »ç½½¿¡¼ ÀüÀÚÀÇ À̵¿ ¹× ´Ù¸¥ ¼¼Æ÷Áú ¹× ¹ÌÅäÄܵ帮¾Æ ºÐÀÚµµ ÇʼöÀûÀÓ.. NAD´Â ÀüÀÚ Àü´ÞÀÇ ÇÙ½É ¿ä¼Ò·Î¼, NADÀÇ È¯¿ø ¹× »êÈ (NADH : NAD+ ) ÇüÅÂÀÇ ºñÀ²Àº »êÈ È¯¿ø Ç×»ó¼ºÀ» ¹Ý¿µÇϸç, ÀÌ´Â ¼¼Æ÷ ±¸È¹ ¹× ´ë»ç ¼Óµµ¿¡ µû¶ó ´Þ¶óÁü.
>LDH(Á¥»ê-Å»¼ö¼ÒÈ¿¼Ò)½Ã½ºÅÛÀº NAD+ : NADH ºñÀ²À» ¹Ý¿µÇϴµ¥, ¹ÌÅäÄܵ帮¾Æ¿¡¼ ¼¼Æ÷Áúº¸´Ù ¾à 100 ~ 1000 ¹è ´õ ³ô°í NAD +: NADH ºñÀ²Àº ½ÅÁø ´ë»ç º¯È¿Í ¹Ýµå½Ã ³ª¶õÈ÷ º´ÇàÇÏ¿© º¯ÇÏÁö´Â ¾ÊÀ½...[ 1 ]. ±×·¯³ª sarcolemma¿¡¼´Â NAD+ : NADH ºñÀ²ÀÌ Áõ°¡Çϸé SIRT1 mRNA¿Í ´Ü¹éÁú ¼öÁØÀÇ ¹ßÇöÀÌ »ó½ÂµÇ¹Ç·Î[ 2 ]. ½ÅÁø ´ë»ç¸¦ Å©°Ô »ó½Âº¯È½ÃÅ°´Â ½Åü ¿îµ¿ÀÌ NAD+ : NADH ºñÀ²À» º¯°æ½ÃÅ´°ú µ¿½Ã¿¡ ±× °á°ú SIRT1ÀÇ °·ÂÇÑ À¯µµ¸¦ ¾ß±âÇÑ´Ù´Â °ÍÀº ´ç¿¬Áö»çÀÓ.À̸ç, ÀÌ´Â ³ú-½ÉÀå-°£-½ÅÀå-°ñ°Ý±Ù¿¡ µÎ·ç ¿µÇâÀ» ¹Ìħ
-----[³»Àμº SIRT1 ¹× ¿ÜÀμº SIRT1 activatorÀÇ ±â´Éµé]-----------
Sirtuin 1Àº S. cerevisiae ¿¡ ÀÖ´Â Sir2 À¯ÀüÀÚÀÇ µ¿Á·Ã¼ÀÎ sirtuin °è¿ ´Ü¹éÁúÀÇ ±¸¼º¿øÀ̸ç sirtuin °è¿ÀÇ ±¸¼º¿øÀº sirtuin ÇÙ½É µµ¸ÞÀÎÀÌ Æ¯Â¡Àε¥ 4 °³ÀÇ Å¬·¡½º·Î ±×·ìÀ» ³ª´®...Àΰ£ÀÇ sirtuinÀÇ ±â´ÉÀº ¾ÆÁ÷ È®Á¤µÇÁö ¾Ê¾ÒÀ¸³ª È¿¸ð ½Ã¸£ÅõÀÎ ´Ü¹éÁúÀº ÈļºÀ¯ÀüÀû À¯ÀüÀÚ Ä§¹¬À» Á¶Àý ÇÏ°í rDNAÀÇ ÀçÁ¶ÇÕÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ½.....Áö±Ý±îÁöÀÇ ¿¬±¸¿¡ µû¸£¸é Àΰ£ ½Ã¸£ÅõÀÎÀº mono-ADP-ribosylÆ®·£½ºÆÛ¶óÁ¦ È°¼ºÀ» °¡Áø ¼¼Æ÷³» Á¶Àý´Ü¹éÁú·Î ±â´ÉÇÒ ¼ö Àִµ¥, ÀÌ À¯ÀüÀÚ¿¡ ÀÇÇØ ÄÚµùµÈ ´Ü¹éÁúÀº sirtuin °è¿ÀÇ Å¬·¡½º¿¡ Æ÷ÇÔµÊ
>[Àν¶¸°]Sirtuin 1Àº Àν¶¸°ÀúÇ×¼ºÀÌ ³ôÀº ¼¼Æ÷¿¡¼´Â ÇÏÇâÁ¶ÀýµÇ¸ç ±× ¹ßÇöÀ» À¯µµÇϸé Àν¶¸°°¨¼ö¼ºÀÌ Áõ°¡ = sirt1ºÐÀÚ°¡ Àν¶¸° °¨¼ö¼º °³¼±°ú °ü·ÃÀÌ ÀÖÀ½À» ½Ã»ç. [9] ¶ÇÇÑ, SIRT1Àº ÇʼöÀûÀÎ ´ë»ç Á¶Àý Àü»ç ÀÎÀÚµéÀÎ PGC1 ¾ËÆÄ / ERR ¾ËÆÄ complexÀÇ ±¸¼º¿ä¼ÒµéÀ» Å»¾Æ¼¼Æ¿È ÇÏ°í ±× È°¼º¿¡ ¿µÇâÀ» ¹Ìħ-
>[p53]Æ÷À¯·ù¿¡¼ SIRT1Àº p53 ´Ü¹éÁú À» Å»¾Æ¼¼Æ¿ÈÇÏ¿© ºñÈ°¼ºÈ½ÃÅ°¸ç autophagy¸¦ ÀÚ±ØÇÔ(=¿·®Á¦ÇÑÀ¸·Î ÀÎÇÑ ¿µ¾çºÐ¼·ÃëÁ¦Çѽà SIRT1ÀÌ ¼±ÅÃÇÏ´Â ´ë¾ÈÀÓ) ....
>[³ëÈ]Àΰ£ÀÇ ³ëÈ´Â chronic, low-grade inflammationÀÌ Æ¯Â¡Àε¥, NF-κB´Â ¿°Áõ°ú °ü·ÃµÈ À¯ÀüÀÚÀÇ ÁÖ¿ä Àü»çÁ¶ÀýÁ¦ÀÓ...sirt1Àº ¶óÀ̽Š310¿¡¼ NF-κBÀÇ RELA / P65 ¼ºê À¯´ÖÀ» Å»¾Æ¼¼Æ¿ ÈÇÏ¿© NF-κB-Á¶Àý À¯ÀüÀÚÀÇ ¹ßÇöÀ» ¾ïÁ¦ÇÔÀ¸·Î½á ¿°Áõ-³ëÈÀÇ °³¼± ÅëÇÑ ¼ö¸í¿¬ÀåÀ» À¯µµÇÔ
>[ÀÚ°¡¸é¿ªÁúȯ] ³»ÀμºSIRT1Àº ¼±Ãµ¸é¿ª¿¡ °ü·ÃµÈ TÇïÆÛ17 ¼¼Æ÷¸¦ È°¼ºÈÇÏ´Â ¿ªÇÒÀ» ¼öÇà......¶§·Î, sirt1È°¼ºÀ¯µµ¸ñÀûÀ¸·Î ¸¸µç ÇÕ¼ºÀǾàÇ° Åõ¿©´Â ÀÚ°¡¸é¿ªÁúȯÀ» À¯¹ßÇϰųª ¾ÇȽÃų ¼öµµ ÀÖÀ½...±×·¯³ª, ¿ÜÀμºSIRT1 activator(¸ÞÆ®Æ÷¸£¹Î, ·¹½ºº£¶óÆ®·Ñ, ¸®¸¶±×¸° µî)Åõ¿©½Ã T17¼¼Æ÷ÀÇ ºÐÈ/È°¼ºÀ» ¾ïÁ¦ÇÔÀÌ È®ÀεǾúÀ½
>[Áßµ¶] SIRT1Àº D1 À¯Çü µµÆĹμº Áß°£°¡½Ã´º·± ³»ÀÇ HDAC1 ¹× AP-1 ÇÁ·Î¸ðÅÍ º¹ÇÕü¿Í ÇÔ²² Áßµ¶ÀÇ º´Àο¡ ¹ÐÁ¢ÇÏ°Ô °ü·ÃµÇ¾î ÀÖÀ½.
>[»óÈ£ ÀÛ¿ë]Sirtuin 1Àº HEY2 , PGC1-alpha , ERR-alpha , ¹× AIRE ¿Í »óÈ£ ÀÛ¿ëÇÏ°í ÀÖÀ½.... Mir-132 ¸¶ÀÌÅ©·ÎRNA´Â Sirtuin 1 mRNA¿Í »óÈ£ÀÛ¿ëÇÏ¿© ´Ü¹éÁú¹ßÇöÀ» °¨¼Ò½ÃÅ´À¸·Î½á ºñ¸¸ÀÚÀÇ Àν¶¸°ÀúÇ×À» À¯µµÇÔ
------------
>>2020.09.24 ¾î¸°ÀÌ¿¡°Õ Èû ¸ø ¾²´Â Äڷγª19... 'ÀÌÀ¯' ¹àÇôÁ³´Ù =Ú¸ ¿¬±¸ÆÀ "¼±Ãµ¼º ¸é¿ª °ÇÑ ´öºÐ"
¾î¸°ÀÌÀÇ Äڷγª19 Áõ»óÀÌ °æ¹ÌÇÑ ÀÌÀ¯¸¦ ¹àÇô³½ ¿¬±¸ °á°ú°¡ ³ª¿Ô´Ù. º¸Åë ¾î¸°À̵éÀº ¼ºÀκ¸´Ù ¸é¿ª·ÂÀÌ ¾àÇØ °°Àº Áúº´¿¡ °É·Áµµ ´õ À§ÇèÇÑ °æ¿ì°¡ ¸¹´Ù. Áö³ 2009³â¿¡ À¯ÇàÇß´ø ½ÅÁ¾Ç÷絵 ¼ºÀκ¸´Ù ¾î¸°ÀÌ¿¡°Ô Ä¡¸íÀûÀ̾ú´Ù. ±×·±µ¥, Äڷγª19ÀÇ °æ¿ì ´Ù¼Ò ´Ù¸¥ ¾ç»óÀ» º¸ÀδÙ. ¾î¸°À̵éÀº Äڷγª19¿¡ °É·Áµµ Áõ»óÀÌ °¡º¿ö ¸¶Ä¡ °¨±âó·³ Áö³ª°¡´Â °æ¿ì°¡ ¸¹Àº °ÍÀÌ´Ù. ÃÖ±Ù ÇмúÁö '»çÀ̾𽺠Áß°³ÀÇÇÐ(Science Translational Medicine)'¿¡´Â ¾î¸°ÀÌÀÇ Äڷγª19 Áõ»óÀÌ °æ¹ÌÇÑ ÀÌÀ¯¸¦ ¹àÇô³½ ¿¬±¸°¡ °ÔÀçµÆ´Ù.
==Äڷγª19 ¼Ò¾Æ ȯÀÚ, '¼±Ãµ¼º ¸é¿ª' ¼öÄ¡ ´õ ³ô´Ù==
¹Ì±¹ ¾Ë¹öÆ® ¾ÆÀν´Å¸ÀÎ ÀÇ°ú´ë ¿¬±¸ÆÀÀº ¹Ì±¹ ´º¿å ¸óÅ×ÇÇ¿À·¹ º´¿ø¿¡ Äڷγª19·Î ÀÔ¿øÇÑ ¼ºÀΠȯÀÚ 65¸í°ú ¼Ò¾Æ ȯÀÚ 65¸íÀ» ºñ±³ ºÐ¼®Çß´Ù. ±× °á°ú, ¼ºÀÎÀº ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ¾ÇÈµÈ ºñÀ²ÀÌ 37%¿´´ø ¹Ý¸é, ¾ÆÀÌ´Â ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ¾ÇÈµÈ ºñÀ²ÀÌ 8%¿¡ ºÒ°úÇß´Ù. »ç¸Á·ü ¶ÇÇÑ ¼ºÀÎÀº 28%, ¼Ò¾Æ´Â 3%·Î Å« Â÷À̸¦ º¸¿´´Ù. ¿¬±¸ÆÀ¿¡ µû¸£¸é ¼Ò¾Æ ȯÀÚ¿¡°Ô¼´Â '¼±Ãµ¼º ¸é¿ª'°ú °ü·ÃµÈ »çÀÌÅäÄ«ÀÎ ¼öÄ¡(IL-17A=Th17A)°¡ ¼ºÀκ¸´Ù »ó´çÈ÷ ³ô°Ô ³ªÅ¸³µ´Ù. ¿¬±¸ÆÀÀº ÀÌ »çÀÌÅäÄ«ÀÎ ¼öÄ¡°¡ ³ôÀ»¼ö·Ï Äڷγª19ÀÇ ÁÖ¿ä Áõ»ó Áß ÇϳªÀÎ '±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS)'ÀÌ »ý±æ À§ÇèÀÌ ÁÙ¾îµç´Ù°í ºÃ´Ù....(Çؼ®)½ÇÀº ¿ÜºÎº´±Õµé¿¡ ´ëÇÑ Th17A ¶Ç´Â IL-17A¼¼Æ÷ÀÇ º¸È£¹ÝÀÀ ±ÕÇüÁ¶ÀýÀÇ ÀûÁ¤¼ºÀÌ °·ÂÇÏ´Ù°í Ç¥ÇöÇØ¾ß ¸Â´Â ¼³¸íÀÓ...¿ø·¡ Th17¼¼Æ÷´Â ¼±Ãµ¸é¿ª°ú ÈÄõ/ÀûÀÀ¸é¿ªÀÇ ±³Â÷·Î¿¡ À§Ä¡ÇϹǷÎ, Th1(CMI°ü·Ã¼¼Æ÷)/Th17ºñÀ²ÀÌ Áß¿äÇѵ¥ Th17¼¼Æ÷¹ÝÀÀÀÌ ³Ê¹« ¾àÇϸé Á¡¸·ÀÇ °¨¿°¼ºÁúȯ ¹ß»ýÀÌ Àæ°í, ³Ê¹« °ÇÏ¸é ¿ÀÈ÷·Á »çÀÌÅäÄ«ÀÎÆødzÀÌ ¾ß±âµÉ ¼ö Àֱ⶧¹®...Th17´Â ¸é¿ª¸Þ¸ð¸®¿Íµµ °ü·ÃµÊ...³»ÀμºSIRT1Àº Th17¼¼Æ÷ÀÇ ¼±Ãµ¸é¿ª ¹× ¸é¿ª±â¾ïÀ» ±ÕÇüÁ¶ÀýÇÔÀ¸·Î½á º¸Á¶ÇÏÁö¸¸, ¿ÜºÎ¿¡¼ Åõ¿©ÇÑ ¿ÜÀμº SIRT1 activator´Â Th17¼¼Æ÷¸¦ È°¼ºÈ Çϱ⵵ ÇÏÁö¸¸ ºÐȹÝÀÀÀ» ¹«µð°Ô Çϱ⵵ ÇÔ( Th17¼¼Æ÷ÀÇ ¿À¹ö½´ÆÃÀ¸·Î ÀÎÇÑ »çÀÌÅäÄ«ÀÎÆødz¹ß»ý ¹æÁö °¡´É)..
==°úµµÇÑ 'ÈÄõ¼º ¸é¿ª'ÀÌ Äڷγª°¨¿° Áõ»ó ¾ÇÈÀÇ ÁÖ¹ü==
»ç¶÷ÀÇ ¸é¿ª ÀÛ¿ë¿¡´Â µÎ °¡Áö À¯ÇüÀÌ ÀÖ´Ù. '¼±Ãµ¼º ¸é¿ª'°ú 'ÈÄõ¼º ¸é¿ª(ÀûÀÀ ¸é¿ª)'ÀÌ´Ù. ¼±Ãµ¼º ¸é¿ªÀº ž ¶§ºÎÅÍ ÀÖ´Â °ÍÀ¸·Î, ¸ðµç Á¾·ùÀÇ º´¿øü°¡ ħÀÔÇßÀ» ¶§ ºü¸£°Ô ¹ÝÀÀÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. ÈÄõ¼º ¸é¿ªÀº ÀÏ´Ü º´¿¡ °É¸° ÈÄ Ç×ü¸¦ Çü¼ºÇØ »ý±â´Â °ÍÀ¸·Î, ƯÁ¤ ¹ÙÀÌ·¯½º³ª ¹Ì»ý¹°À» Ç¥ÀûÀ¸·Î ¹ÝÀÀÇÏ´Â °ÍÀÌ´Ù. ¿¹ÄÁ´ë È«¿ª¿¡ ÇÑ ¹ø °É¸° ÈÄ¿¡´Â ´Ù½Ã °É¸®Áö ¾Ê°Å³ª, ÀΰøÀûÀ¸·Î Ç׿øÀ» ¸¸µé¾î ü³»¿¡ ÁÖ»çÇØ Æ¯Á¤ ÁúȯÀ» ¿¹¹æÇÏ´Â µî ¹æ½ÄÀÌ ÈÄõ¼º ¸é¿ª¿¡ ÇØ´çÇÑ´Ù.
Äڷγª19·Î »ç¸ÁÇ߰ųª, ±â°è È£ÈíÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ½É°¢ÇÑ Áõ»óÀ» º¸ÀΠȯÀÚµéÀº ¹«»çÈ÷ ȸº¹ÇÑ È¯Àڵ麸´Ù 'ÁßÈÇ×ü' ¼öÄ¡°¡ ³ô¾Ò´Ù. ÁßÈÇ×ü´Â ÈÄõÀû ¸é¿ª ÀÛ¿ëÀ¸·Î ÀÎÇØ »ý±â´Â °ÍÀ¸·Î, ƯÁ¤ ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ÈÄ ±×¿¡ ´ëÀÀÇØ ¸¸µé¾îÁö´Â Ç×ü´Ù. ¿¬±¸ÆÀÀº À̸¦ ±Ù°Å·Î ½ÉÇÑ Äڷγª19 Áõ»óÀÌ Áö³ªÄ£ ÀûÀÀ ¸é¿ªÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ÃßÃøÇß´Ù. ¸é¿ª ¹ÝÀÀÀÌ Á¦´ë·Î ÀÌ·ïÁöÁö ¾Ê¾Æ¼ Áõ»óÀÌ ½ÉÇØÁø °ÍÀÌ ¾Æ´Ï¶ó, ¿ÀÈ÷·Á °úµµÇÑ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇØ ¿°Áõ ¹ÝÀÀÀÌ ½ÉÇÏ°Ô ³ªÅ¸³µ´Ù´Â Àǹ̴Ù.
=="ÇöÀç °³¹ß Áß ¹é½Å, µµ¿ò ¾È µÉ °¡´É¼º ÀÖ´Ù"==
À̹ø ¿¬±¸ °á°ú´Â ¾ÕÀ¸·Î Äڷγª19 ¹é½ÅÀ» ¸¸µå´Â µ¥µµ À¯ÀǹÌÇÑ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀδÙ. ¿¬±¸¸¦ ÁÖµµÇÑ ºª½Ã ÇØ·Ñµå ¹Ú»ç´Â "ÇöÀç °³¹ß ÁßÀÎ ´ëºÎºÐÀÇ ¹é½Å È帴 ÁßÈÇ×ü ¼öÁØÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ°í ÀÖ´Ù"¸ç "±×·¯³ª ÁßÈÇ×ü°¡ dzºÎÇÑ Ç÷ÀåÀº ÀÌ¹Ì Áõ»óÀÌ ³ªÅ¸³ ¼ºÀο¡°Ô µµ¿òÀÌ µÇÁö ¾ÊÀ» °¡´É¼ºÀÌ ÀÖ´Ù"°í ¸»Çß´Ù. ±×´Â À̾î "Äڷγª19 ¹é½Å¿¡ ¼±Ãµ¼º ¸é¿ªÀ» ³ôÀÌ´Â µî ´Ù¸¥ ¹æ¹ýÀ¸·Î ¸é¿ªÀ» ÃËÁøÇÏ´Â ¹é½ÅÀ» °í·ÁÇغ¼ ¼ö ÀÖÀ» °Í"À̶ó°í µ¡ºÙ¿´´Ù.
--TH17A=IL-17A¸¦ ¸¸µé¾î³»´Â Th¼¼Æ÷±º. °ÅÀÇ ¸ðµç ÀÚ°¡¸é¿ªÁúȯ(SLE, RA, °Á÷¼ºÃ´Ãß¿° µî)À» À¯¹ß--MSM ¹× sirt1È°¼ºÁ¦¿¡ ¹ÝÀÀÇÔ.
T ÇïÆÛ 17 (Th17) ¼¼Æ÷´Â CD4+ T ¼¼Æ÷ÀÇ Áß¿äÇÑ subset ::: ½Åü Á¶Á÷À» ħ¹üÇÑ ¼¼Æ÷¿Ü °¨¿°¼º º´¿øü¸¦ Á¡¸·Ç¥¸é¿¡¼ Á¦°ÅÇÏ´Â ±âÀü ¼öÇà¿¡ ¸Å¿ì Áß¿ä....¸é¿ª¿¡ ÀÖ¾î¼ Th17 ¼¼Æ÷ÀÇ ±ØÈ÷ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÏ°í ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ¸é¿ªÃ¼°è°¡ ÀÌ Th17¼¼Æ÷ À¯ÇüÀÇ »ý»ê ¹× À¯Áö¸¦ ¾î¶² ¹æ½ÄÀ¸·Î Á¶ÀýÇÏ°í ÀÖ´ÂÁö´Â ¾ÆÁ÷ ¿ÏÀüÈ÷ È®¸³µÈ »óÅ´ ¾Æ´Ô, ƯÈ÷, ÀÌ·¯ÇÑ ¼¼Æ÷ÀÇ °¡¼Ò¼º ¶Ç´Â ´Ù¸¥ CD4+ T¼¼Æ÷ subset·Î Àüȯ ºÐÈÇÏ´Â µ¿Àû ´É·ÂÀº ´ëºÎºÐ Ư¼ºÈµÇÁö ¾ÊÀº ä ³²¾Æ ÀÖÀ½..........¸é¿ªÃ¼°è°¡ °É·¯³»Áö ¸øÇÑä ü³»¿¡ ³²°Ô µÇ¸é IL-17°°Àº ¿°ÁõÇâcytokinesÀÇ Áõ»ê ÅëÇØ ¾Ë·¹¸£±â ¹× ÀÚ°¡¸é¿ªÁúȯÀÌ ¾ß±âµÊ........ÇÑÆí naive T cell¿¡¼ Th-17cell·ÎÀÇ ºÐÈ´Â È°¼ºÈµÈ Ç׿ø»ý»ê¼¼Æ÷µéÀÌ ºÐºñÇϴ ƯÁ¤ cytokinesµéÀÌ ÀÖ¾î¾ß Çϴµ¥ IL-6(¶Ç´Â IL-21)¹× TGF-beta°¡ ºÐÈ¿¡ ÀÖ¾î ÀÚ±ØÁ¦·Î ÀÛ¿ëÇϸç, TNF-alpha, IL-1beta, IL_23, sodiumµîÀº ºÐȸ¦ ´õ °È½ÃÅ´ Áï, Th17 ¼¼Æ÷ À¯µµ´Â IL-6¿Í TGF β ¶Ç´Â IL-21°ú TGF βÀÇ Á¶ÇÕÀ» ÅëÇØ ¹ß»ý.......ÇÑÆí, VD, retinoic acid, SOCs1m SOCs3µîÀº Th17ºÐȾïÁ¦¿¡ °ü¿©.....ºÐÈµÈ Th17 ¼¼Æ÷´Â IL-17A, IL-17F, IL-21, IL-22, GM-CSF, IL-9, IL-10 ¹× IFN γ ¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ »çÀÌÅäÄ«ÀεéÀ» »ý»êÇϸç, ÀÌ´Â »çÀÌÅäÄ«ÀΠȯ°æ¿¡ µû¶ó ´Ù¸§.....Th17°èÅëÀ¸·Î Á¤ÀÇµÈ key transcription factors·Î´Â retinoic acid receptor-related orphan receptor(ROR)-gamma(RORgamma) ¹× RORalphaµîÀÌ ÀÖÀ½....³ªÀ̺ê CD4+T ¼¼Æ÷¸¦ Th17 ºÐÈ·Î À¯µµÇÏ´Â µ¥ °ü·ÃµÈ ´Ù¸¥ Àü»ç ÀÎÀڷδ STAT3, ÀÎÅÍÆä·Ð Á¶Àý ÀÎÀÚ 4 (IRF4), ¾Æ¸± źȼö¼Ò ¼ö¿ëü (AHR), NOTCH ¹× BATF°¡ ÀÖÀ½.........RA SLE, BA, MS, Psorisis, IBD(CD/UC), type1DM ¸ðµÎ Th17º´ÀαâÀüÀÌ °ü·ÃµÊ.....HCQ´Â Th17°³Ã¼±º °¨¼Ò¸¦ ÅëÇØ IL-6, IL-17 ¹× IL-22ÀÇ »ý¼ºÀ» ¾ïÁ¦ÇÔÀ¸·Î½á SLE Áõ»óÀ» °³¼±...
....¸»ÃÊÇ÷¾×¿¡¼ º¼ ¼ö ÀÖ´Â T cell subsetÁß¿¡¼ ¿°ÁõÇâ subset¿¡´Â Th1 ¹× Th17, Ç׿°Áõsubset¿¡´Â Th2¿Í Treg°¡ ÀÖÀ¸¸ç ¿°Áõ½Ã¿¡´Â ¿°ÁõÇâsubsetÀÇ »ó½Â, Ç׿°ÁõsubsetÀÇ ÀúÇϸ¦ º¼ ¼ö ÀÖÀ¸¸ç Th1°ú Th17»çÀÌ¿¡´Â ¼·Î moderate negative correlationÀ» º¸ÀÓ...´õºÒ¾î ´ÜÇÙ±¸(Mo)¿Í ÀÚ¿¬»ìÇؼ¼Æ÷(NK)subsetÀ» Æ÷ÇÔÇÏ´Â innate immunity¿¡¼ Áõ¿äÇÑ È°µ¿Ã¼µé·Î´Â IL-1beta, IL-6, IFN-gammaµî ¿°ÁõÇâ »çÀÌÅäÄ«ÀεéÀº »ó½Â, ¹Ý¸é¿¡ Ç׿°Áõ»çÀÌÅäÄ«ÀÎÀÎIL-10Àº ÀúÇÏµÊ .....Th17¼¼Æ÷¿Í Treg¼¼Æ÷´Â °øÈ÷ CD4+T cell¿¡ ¼ÓÇÏÁö¸¸ Th17Àº ¿°Áõ¾ÇÈ, Treg(Treg17)Àº ¿°ÁõÀúÇÏÈ¿°ú¹ßÇöÀ» ¼öÇàÇÔ
--------[Th17¼¼Æ÷ Á¤¸®]-------
Th17, Th17 cells, T helper 17 cells´Â ¿°Áõ Àü(proinflamm.) µµ¿òT ¼¼Æ÷ Áß¿¡¼ ÀÎÅÍ·çŲ17 (IL-17)À» »ý¼ºÇÏ´Â Áý´ÜÀ» ¶æÇÑ´Ù. ±×µéÀº Á¶Àý T ¼¼Æ÷¿Í °ü·ÃµÇ¸ç, Th17sÀ» ºÐȽÃÄÑ ½ÇÁ¦ Á¶Àý T¼¼Æ÷ ºÐȸ¦ ¾ïÁ¦ÇÏ´Â ½ÅÈ£µé°ú °ü·ÃµÈ´Ù. ÇÏÁö¸¸, Th17s´Â ¹ß´Þ»ó¿¡ ÀÖ¾î¼ Th1, Th2¿Í´Â ºÐ¸íÈ÷ ±¸º°µÈ´Ù. Th17¼¼Æ÷´Â Á¡¸· À庮À» À¯ÁöÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Á¡¸· Ç¥¸é¿¡¼ º´¿øü¸¦ ¾ø¾Ö´Âµ¥ ±â¿©ÇÑ´Ù. ÇÏÁö¸¸ ÀÌ ¼¼Æ÷±ºÀÇ È°¼º(Áõ½Ä-ºÐÈ)°ú´Ù ¹× Á¶ÀýÀå¾Ö(=Treg.cell°¨¼Ò)´Â ´Ù¹ß¼º°æÈÁõ, RA, SLE, ±â°üÁöõ½Ä, IBD(CD/UC), Á¦1ÇüDM µî ÀÚ°¡¸é¿ª Áúȯ°ú ¿°Áõ¼º Áúº´°ú ¿¬°üµÇ¸ç, ¹Ý¸é¿¡ Á¡¸· Ç¥¸é¿¡¼ Th17¼¼Æ÷°¡ ÁÙ¾îµå´Â °ÍÀº ¸¸¼º ¿°Áõ°ú ¹Ì»ý¹°ÀÌ ÀüÀ̵Ǵ °Í°úµµ ¿¬°üµÈ´Ù.
==Th17 ¼¼Æ÷ÀÇ ºÐÈ
º´¿øü¿Í Á¢ÃËÇÑ ÈÄ È°¼ºÈµÈ Ç׿øÁ¦½Ã¼¼Æ÷(APCs, antigen presenting cells)·ÎºÎÅÍ »ý»êµÇ´Â »çÀÌÅäÄ«Àεé, Áï ÇüÁúÀüȯ Áõ½Ä ÀÎÀÚ º£Å¸ (TGF-β), ÀÎÅÍ·çŲ6 (IL-6), ÀÎÅÍ·çŲ21 (IL-21) ÀÎÅÍ·çŲ23 (IL-23) µîÀº naive(¹ÌÁ¢ÃË) T cell·Î ºÎÅÍ Th17ÀÇ ºÐÈ(Àüȯ)¿¡ ±â¿©ÇÑ´Ù´Â °ÍÀÌ Áã¿Í »ç¶÷¿¡¼ È®ÀεƴÙ. À̶§ Th17 ¼¼Æ÷ ºÐÈÀÇ Áß¿äÁ¶Àý Ÿ°ÙÀ¸·Î´Â Stat3 (Signal transducer and the activator of transcription 3)°ú RORγ(retinoic acid receptor-related orphan receptors gamma)¿Í RORα µîÀÌ ÀÖ´Ù. Th17¼¼Æ÷´Â ±Ã±ØÀûÀ¸·Î ±×µéÀÇ ºÐÈ ÇÁ·Î±×·¥À» ¹Ù²ã¼ º¸È£ ¼¼Æ÷(¼±Ãµ¸é¿ª °ü·Ã) ¶Ç´Â Àü¿°Áõ¼º(proinflamm.) º´¿ø¼º ¼¼Æ÷°¡ µÇµµ·Ï Çϴµ¥, IL-6°ú TGF-β¿¡ ÀÇÇØ À¯µµµÇ¸ç ¼±Ãµ¸é¿ªÀ» ´ã´çÇÏ´Â(º¸È£ÀÛ¿ëÀ» ÇÏ´Â) ºñº´¿ø¼ºÀÇ Th17¼¼Æ÷´Â µû·Î Treg17 ¼¼Æ÷¶ó µû·Î ÁöĪÇϸç, Àü¿°Áõ¼º(º´¿ø¼º...proinflamm.cytokineºÐºñÀÇ ÁÖ¹ü) Th17¼¼Æ÷´Â IL-23°ú IL-1β¿¡ ÀÇÇØ ÁÖ·Î À¯µµµÈ´Ù. Th17¼¼Æ÷ Àڽſ¡ ÀÇÇØ »ý¼º-ºÐºñµÇ´Â(autocrine) IL-21´Â Th17¼¼Æ÷ÀÇ ¶Ç´Ù¸¥ ºÐÈ°æ·Î¸¦ ¹ßµ¿½ÃÅ°°Ô µÇ¸ç, ÇÑÆí. Th1ÀÇ ÁÖ¿ä ºÐÈÀÎÀÚÀÎ ÀÎÅÍÆä·Ð°¨¸¶(IFNy)¿Í Th2 ºÐÈÀÇ ÁÖ¿ä È°¼ºÀÎÀÚÀÎ IL-4µéÀº ¸ðµÎ Th17ÀÇ ºÐȸ¦ ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
==Th17 ¼¼Æ÷ÀÇ ±â´É
Th17 ¼¼Æ÷´Â º´¿øü·ÎºÎÅÍ ¸öÀ» º¸È£ÇÏ´Â ÀûÀÀ ¸é¿ª¿¡ÀÖ¾î¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ÇÏÁö¸¸, °õÆÎÀ̱տ¡ ´ëÇ×ÇÏ´Â ¸é¿ªÀº ƯÁ¤ºÎÀ§¿¡¸¸ Á¦ÇÑÀûÀ¸·Î ³ªÅ¸³ª¸ç Çطοî È¿°úµéÀÌ °üÂûµÇ¾ú´Ù. ±×µéÀÇ ÁÖ¿ä È¿°ú »çÀÌÅäÄ«ÀÎ(effector cytokines)Àº IL-17A, IL-17F, IL-21°ú IL-22 µîÀÌ´Ù. Th17Àº Á¾¾çÀÇ À§ÃàÀ» ¸Å°³Çϴ°ÍÀÌ Áã¿¡¼ ³ªÅ¸³µÁö¸¸ ¶ÇÇÑ °áÀå(colon)ÀÇ ¿°Áõ¿¡ ÀÇÇØ ÀڱصǾî Á¾¾çÇü¼ºÀ» ÃËÁøÇÏ´Â °á°ú ¶ÇÇÑ Áã¿¡¼ ³ªÅ¸³µ´Ù. ´Ù¸¥ µµ¿ò T ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î, Th17 ¼¼Æ÷´Â º´¿øü¿¡ ¹ÝÀÀÇϴµ¥ ÀÖ¾î B¼¼Æ÷¿Í ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÈ´Ù. Th17¼¼Æ÷´Â CXCL13 Å°¸ðÄ«ÀÎ(chemokine) ½ÅÈ£Àü´ÞÀ» ÅëÇØ B¼¼Æ÷ º¸°°ú °ü·ÃµÇ¸ç, Th17 È°¼ºÀº Ç×ü Çü¼ºÀ» µµ¿ï ¼ö ÀÖ´Ù.
==Th17¼¼Æ÷ °ü·Ã Áúº´
Th17¼¼Æ÷ÀÇ Á¶ÀýÀå¾Ö´Â ÀÚ°¡¸é¿ª Áúȯ°ú ¿°Áõ¿¡ °ü·ÃµÈ´Ù. ÀÚ°¡¸é¿ª¼º ÁúȯÀÇ °æ¿ì, Th17¼¼Æ÷ÀÇ °úµµÇÑ È°¼ºÀº ·ù¸¶Æ¼½º °üÀý¿°ÀÇ °æ¿ìó·³ ºÒÇÊ¿äÇÏ°Ô ¸¹Àº ¾çÀÇ ¿°ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. Th17¼¼Æ÷´Â Á¡¸· ¸é¿ªÀ» À¯ÁöÇϴµ¥ ÇÊ¿äÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. HIVÀÇ °æ¿ì¸¦ º¸¸é, Th17¼¼Æ÷°¡ ÁÙ¾îµå´Â°ÍÀÌ ¸¸¼º ¿°Áõ¿¡ ±â¿© ÇÒ ¼öµµ ÀÖ´Ù.
---[SIRT1 activatorÅõ¿©ÀÇ ÀÕÁ¡ Á¤¸®]----------
[[Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation]]
<ÁßÁ¡Á¤¸®>
=SIRT1È°¼ºÁ¦´Â activation impedes Th17 cell ÀÇ STAT3 deacetylation ¹× Rorc promoter°áÇÕ´ÉÀ» ¾ïÁ¦½ÃÅ°¸ç ±× °á°ú Th17ºÐȸ¦ ¾ïÁ¦ÇÔÀ¸·Î½á »ýÁã¿¡¼ Á¾¾ç¼ºÀåÀ» ¾ïÁ¦ÇÏ°í ȯÀÚ¿¡¼ TRh17 ºóµµ¸¦ °¨¼Ò½ÃÄ×À¸¸ç, SIRT1 activators [¸®¸¶±×¸°, ¸ÞÆ®Æ÷¸£¹Î, ·¹½ºº£¶óÆ®·Ñ]µéÀº ¾ÏȯÀڵ鿡°Ô¼µµ IL-17A protumor functionsÀ» Á÷Á¢ ¾ïÁ¦ Ÿ°ÙÆÃÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖÀ½
<¹è°æ>
Sirtuin-1Àº ƯÁ¤´Ü¹éÁúÀÇ Å»¾Æ¼¼Æ¿È¸¦ ÅëÇØ ´Ù¾çÇÑ ¼¼Æ÷ÀÇ ¿°Áõ°úÁ¤¿¡ ÀÖ¾î¼ °áÁ¤ÀûÀÎ Á¶ÀýÀÚÀÓÀÌ ÀÔÁõµÇ¾úÀ½
³»Àμº(Basal) SIRT1 È°¼ºÀº (»ýÁã½ÇÇè»ó)Th9À» Á¦ÇÑÇÏ°í Th17ºÐȸ¦ Áõ°¡½ÃÄ×À¸³ª, ¾à¸®ÇÐÀû(È°¼ºÁ¦¸¦ ¿ÜºÎ¿¡¼ Åõ¿©) SIRT1 activationÀÇ T¼¼Æ÷ ºÐÈ ¹× Ç×Á¾¾ç¹ÝÀÀÀº ºÒºÐ¸íÇß¾ú´Âµ¥, ÀúÀÚµéÀÇ ½ÇÇè°á°ú·Î µå·¯³ °ÍÀº SIRT1 pharmacological agonists Åõ¿©·Î »ýÁã¿Í »ç¶÷¿¡°Ô¼ °øÈ÷ Th17¼¼Æ÷ ºÐȸ¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦ÇÑ´Ù´Â °ÍÀÓ
SIRT1 activationÀº Th17¼¼Æ÷³»¿¡¼ ^STAT3 deacetylationÀ» Â÷´ÜÇÏ¿© ÇÙ³»·ÎÀÇ ÀüÀ§, RorC ÇÁ·Î¸ðÅÍ¿¡ °áÇÕÇÏ¿© Àü»ç À¯µµµÇ´Â ¸ðµç ´É·ÂÀ» °¨¼Ò½ÃÄ×°í ¶ÇÇÑ, Th17¼¼Æ÷ÀÇ IL-17A,F ¹× IL-21, 22, 23R ºÐºñ¸¦ Â÷´ÜÇÔÀ¸·Î½á ±× ÇϺÎÀÇ ¹ÝÀÀµé, Áï VEGF-A »ý»ê-->Á¾¾ç¼ºÀå ¹× Ç÷°ü½Å»ýÀÇ ¸ðµç °úÁ¤À» ¾ïÁ¦½ÃÅ´À¸·Î½á tomor microenvironmemet¸¦ °áÁ¤ÀûÀ¸·Î ¾ïÁ¦ÇÔÀÌ È®ÀεǾúÀ½(wet typeAMD¾ïÁ¦µµ!!)
SIRT1 agonistsÅõ¿©´Â Th17 cell differentiationÂ÷´ÜÀ» ÅëÇØ °á±¹ »ýÁã¿¡¼ Á¾¾ç¼ºÀåÀ» °¨¼Ò½ÃÄ×°í ¾ÏȯÀڵ鿡°Ô Åõ¿©ÇÑ SIRT1 agonist ¸ÞÆ®Æ÷¸£¹ÎÀº Th17¼¼Æ÷ÀÇ ºÐÈºóµµ¿Í STAT3 acetylation levelsÀ» ¸ðµÎ ÀúÇϽÃÄ×À½..... °á·ÐÀûÀ¸·Î, SIRT1 activators µéÀº IL-17A±â´ÉÀ» Á÷Á¢ Ÿ°ÙÆÃÇؼ Th17ºÐȸ¦ ¾ïÁ¦ÇÔ ÅëÇØ Á¾¾ç¼ºÀåÀ» ¾ïÁ¦ÇÑ´Ù°í º¼ ¼ö ÀÖÀ½
--------------
>>2020.09.25 ¿îµ¿ÀÇ ³î¶ó¿î È¿°ú… Äڷγª19µµ ¾ïÁ¦ÇÑ´Ù°í
±ÙÀ° È£¸£¸ó 'À̸®½Å'ÀÇ ´Ù¾çÇÑ È¿´É
¿îµ¿ÇÏ¸é ±ÙÀ°¿¡¼ ºÐºñµÇ´Â À̸®½Å È£¸£¸óÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÑ´Ù´Â »ç½ÇÀÌ ¹àÇôÁ³´Ù. ¿îµ¿ÇßÀ» ¶§ ºÐºñµÇ´Â È£¸£¸ó ‘À̸®½Å(Irisin)’ÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÑ´Ù´Â ¿¬±¸°¡ ³ª¿Ô´Ù.
»óÆÄ¿ï·çÁÖ¸³´ë ¹Ì¸®¾Æ³× µ¥ ¿Ã¸®º£À̶ó ¹Ú»çÆÀÀÌ ÇмúÁö 'ºÐÀÚ ¼¼Æ÷ ³»ºÐºñÇÐ(Molecular and Cellular Endocrinology)'¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é ¿îµ¿À» ÇÏ¸é ±ÙÀ°¿¡¼ ³ª¿À´Â È£¸£¸ó ‘À̸®½Å’ÀÌ Äڷγª19 Ä¡·á È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³´Ù.
¿îµ¿È£¸£¸ó À̸®½Å, Äڷγª19 ¾ïÁ¦ È¿°ú
¿¬±¸ÆÀÀº Äڷγª19 ¹ÙÀÌ·¯½º º¹Á¦¿Í °ü·ÃµÈ 1¸¸4857°³ À¯ÀüÀÚ¸¦ ´ë»óÀ¸·Î À̸®½ÅÀÇ È¿°ú¸¦ ½ÃÇèÇß´Ù.
±× °á°ú, À̸®½Å È£¸£¸óÀÌ TLR3, HAT1, HDAC2 µî À¯ÀüÀÚ ¹ßÇöÀ» ÁÙ¿©, Äڷγª19 ¹ÙÀÌ·¯½º º¹Á¦ÀÇ ÇÙ½É À¯ÀüÀÚ ‘ACE-2’¸¦ ¾ïÁ¦ÇÑ´Ù´Â »ç½ÇÀ» ¹àÇô³Â´Ù. ACE-2 À¯ÀüÀÚ´Â Äڷγª ¹ÙÀÌ·¯½º°¡ ½Åü¿¡ ħÅõÇÏ´Â µ¥ ¾²ÀÌ´Â ¼ö¿ëü´Ù.
¶Ç ¿¬±¸ÆÀÀº À̸®½ÅÀÌ Äڷγª19 ¹ÙÀÌ·¯½º°¡ ½Åü¿¡¼ º¹Á¦µÇ´Â °ÍÀ» ¸·´Â ‘TRIB3 À¯ÀüÀÚ’ÀÇ º¹»ç ¼öÁØÀ» 3¹è·Î ³ôÀδٴ °Íµµ ¹àÇô³Â´Ù. ¿¬±¸ÆÀÀº “TRIB3 À¯ÀüÀÚ°¡ ºÎÁ·Çϸé Áý´Ü°¨¿°¿¡ ½±°Ô ³ëÃâµÇ´Â µî Äڷγª19 ¹ÙÀÌ·¯½º ¾ïÁ¦¿¡ Áß¿äÇÏ´Ù´Â »ç½ÇÀº ¿©·¯ ¿¬±¸¿¡¼ ÀÔÁõµÆ´Ù”¸ç “TRIB3´Â ³ªÀÌ°¡ µé¼ö·Ï °¨¼ÒÇϹǷΠ°í·ÉÃþÀº ƯÈ÷ ÁÖÀÇÇØ¾ß ÇÑ´Ù”°í ¸»Çß´Ù.
¹ÙÀÌ·¯½º ¾ïÁ¦»Ó ¾Æ´Ï¶ó »À, ³ú Æ°Æ°ÇÏ°Ô ¸¸µé¾î
¿îµ¿È£¸£¸ó À̸®½ÅÀº Äڷγª19 ¹ÙÀÌ·¯½º ¾ïÁ¦»Ó ¾Æ´Ï¶ó Àü½Å¿¡ ´Ù¾çÇÑ °Ç° È¿°ú¸¦ ÁØ´Ù°í ¾Ë·ÁÁ³´Ù.
¹Ì±¹ ÇϹöµåÀÇ´ë ºê·ç½º ½ºÇÇ°Ö¸¸ ±³¼öÆÀÀº 2018³â À̸®½ÅÀÌ »À¸¦ Æ°Æ°ÇÏ°Ô ¸¸µç´Ù´Â »ç½ÇÀ» ¹àÇô³Â´Ù. ¿¬±¸ÆÀÀº ¼¼Æ÷½ÇÇèÀ» ÅëÇØ À̸®½ÅÀÌ À¯ÇØÇÑ °ú»êȼö¼Ò·ÎºÎÅÍ °ñ¼¼Æ÷¸¦ º¸È£ÇÏ°í, »À¸¦ ´Ù½Ã ¸¸µå´Â ‘½ºÅ¬·¹·Î½ºÆ¾ ´Ü¹éÁú’ »ý»êÀ» ´Ã¸°´Ù´Â »ç½Çµµ Áõ¸íÇß´Ù.
À̸®½ÅÀº Ä¡¸Åµµ ¿¹¹æÇÏ´Â È¿°ú°¡ ÀÖ´Ù. ¹Ì±¹ Ä÷³ºñ¾Æ´ëÇÐ ÀÇ´ë ¿ÀŸºñ¿À ¾Æ¶õ½Ã¿À ¹Ú»çÆÀÀº 2019³â ±â¾ïÀ» ´ã´çÇÏ´Â ‘Çظ¶’¿¡ À̸®½ÅÀÌ Á¸ÀçÇÏ°í, Ä¡¸Å ȯÀÚ Çظ¶¿¡´Â Á¤»óÀκ¸´Ù À̸®½ÅÀÌ Àû´Ù´Â »ç½ÇÀ» ¿¬±¸¸¦ ÅëÇØ ¹àÇô³Â´Ù.
¿¬±¸ÆÀÀÌ ÁãÀÇ Çظ¶¿¡¼ À̸®½ÅÀ» ¾ø¾ÖÀÚ ³ú¿¡¼ ½ÅÈ£Àü´Þ ±â´ÉÀ» ÇÏ´Â '½Ã³À½º'°¡ ¾àÇØÁö¸é¼ ±â¾ï·ÂÀÌ ¶³¾îÁö´Â °ÍÀ» È®ÀÎÇß´Ù. ¹Ý´ë·Î À̸®½ÅÀ» ´Ã¸®ÀÚ ½Ã³À½º ±â´É°ú ±â¾ï·ÂÀÌ È¸º¹µÆ´Ù. ÇöÀç Ä÷³ºñ¾Æ´ëÇÐ ¿¬±¸ÆÀÀº À̸®½ÅÀ» Ä¡¸Å Ä¡·á¿¡ Àû¿ëÇÏ´Â ¿¬±¸¸¦ ÁøÇàÇÏ°í ÀÖ´Ù.
À̸®½ÅÀº Áö¹æÀ» ‘°¥»öÁö¹æ’À¸·Î ¹Ù²ã üÁßÀ» °¨¼Ò½ÃÅ°´Â È¿°úµµ ÀÖ´Ù. Áß¼ºÁö¹æ°ú ÁöÁú·Î ÀÌ·ïÁø ‘¹é»öÁö¹æ’ÀÌ ¿°ÁõÀ» ÀÏÀ¸Å°´Â °Í°ú ´Þ¸®, °¥»öÁö¹æÀº Ç÷´çÀ» ºÐÇØÇÏ°í, üÁß Á¶Àý¿¡ µµ¿òÀ» ÁØ´Ù. ¶Ç À̸®½ÅÀº ¸é¿ªÃ¼°è¸¦ ÀÛµ¿½ÃÅ°´Â ‘»çÀÌÅäÄ«ÀÎ’À» ¹æÃâÇÏ°í ¿°ÁõÀ» Àâ¾Æ¸Ô´Â ‘´ë½Ä¼¼Æ÷’µµ È°¼ºÈ½ÃÄÑ ¹ÙÀÌ·¯½º·ÎºÎÅÍ ¸öÀ» º¸È£ÇØÁØ´Ù.
À̹ø ¿¬±¸¿¡¼ ¿Ã¸®º£À̶ó ¹Ú»çÆÀÀº Áö¹æ Á¶Á÷ÀÌ ‘Äڷγª19 ¹ÙÀÌ·¯½º ÀúÀå¼Ò’·Î ¾²Àδٴ °Íµµ ¹ß°ßÇß´Ù. ¿¬±¸ÆÀÀº “ºñ¸¸ÀÎ »ç¶÷Àº ÀϹÝÀκ¸´Ù À̸®½Å ¼öÄ¡°¡ ³·°í, ACE-2 ¼ö¿ëü ¼öÄ¡°¡ ³ôÀº °æÇâÀÌ ÀÖ´Ù”¸ç “ÀÌ´Â ºñ¸¸ÀÎ »ç¶÷¿¡°Ô ½É°¢ÇÑ Áúº´ÀÌ ¹ß»ýÇÒ À§ÇèÀÌ ´õ Å©´Ù´Â °ÍÀ» º¸¿©ÁØ´Ù”°í ¸»Çß´Ù.
¿îµ¿À» ÅëÇØ À̸®½ÅÀÌ ºÐºñµÇ¸é Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ°í, Áõ»óÀ» ¾ÇÈÇÏ´Â ºñ¸¸±îÁö °³¼±ÇÏ´Â ÀÌÁß È¿°ú°¡ ÀÖ´Ù°í ¼³¸íÇß´Ù. ¿Ã¸®º£À̶ó ¹Ú»ç´Â “À̹ø ¿¬±¸´Â Äڷγª19 Ä¡·áÀÇ ½Ç¸¶¸®¸¦ ¹ß°ßÇÑ °Í”À̶ó¸ç “À̸®½ÅÀÌ Äڷγª19 ¹ÙÀÌ·¯½º¸¦ ¾î¶»°Ô Á¶ÀýÇÏ´ÂÁö ÆľÇÇÏ´Â Ãß°¡ ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù”°í ¸»Çß´Ù.
===========
[[Can Activation of NRF2 Be a Strategy against COVID-19]]
[[SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate]]
**((ÃÖÁ¾Á¤¸®))nrf2 down-regulation, IFN-1°¨¼Ò//ACE2¹ßÇöÁõ°¡, TGF-1betaÁõ°¡, TLR-4Áõ°¡°¡ Ư¡ÀÎ COVID19°¨¿°½Ã nrf2 activators Åõ¿©·Î ¾ò´Â ÀÕÁ¡µé^^1)ù¹ø° È¿°ú´Â free nrf2Áõ°¡·Î ¼¼Æ÷¸·ÀÇ ACE2¹ßÇöÀÌ °¨¼Ò, ±× °á°ú ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ ¹ÙÀÌ·¯½ºÄ§ÀÔÀ» ¾ïÁ¦ÇÔ, ÇÑÆí, nrf2 activator Åõ¿©È¿°ú´Â Ç×¹ÙÀÌ·¯½º¹ÝÀÀ°ú °ü·ÃµÈ IFNÈ°¼º°ú ÀüÇô ¹«°üÇÔ(nrf2´Â ¿ø·¡ ACE2Áõ»ê ¹× ¼¼Æ÷¸· ¹ßÇöÀ» ¾ïÁ¦ + ÀÎÅÍÆä·ÐÀ¯ÀüÀÚÀÚ±Øü(STING) ¹× IRF3 ¹ßÇöÀ» ¾ïÁ¦ÇÔ=IFN°¨¼Ò...IFN-1ÀÇ Ç×¹ÙÀÌ·¯½º±âÀü±îÁö °í·ÁÇÑ´Ù¸é VC¸¦ ÇÔ²² Åõ¿©ÇÏ´Â °ÍÀ» °í·Á!!...nrf2 activatorÀÛµ¿±âÀüÀº ·½µ¥½Ãºñ¸£³ª HCQÀÛµ¿±âÀü°ú °ãÄ¡Áö¾ÊÀ½ÀÌ È®ÀεǾúÀ½!!).....ÀÚ¼¼È÷ º¸¸é, p62-induced nrf2 activation°ú À¯»çÇÏ°Ô ÀÛ¿ëÇÔ...¼¼Æ÷Áú³» Protein kinase R(PKR)ÀÌ p62¸¦ ÀÛµ¿ÇÏ¿© keap1-nrf2º¹ÇÕü»óÅ¿¡¼ nrf2 inhibitorÀÎ keap1À» Å»¶ô½Ãzl°í ±× °á°ú Áõ°¡µÈ free nrf2°¡ ÇÙ³»·Î À̵¿ÇÏ¿© Àü»çµÊ, À̷νá AREÀ¯ÀüÀڷκÎÅÍ Ç×»êÈÈ¿¼Ò ¹× Á¦2»óÇص¶°ü·ÃÈ¿¼Ò°¡ Áõ»êµÇ°í ^^2)±× °á°ú ¹ÙÀÌ·¯½º°¨¿°À¸·Î ÃË¹ßµÈ ¿°ÁõÇâ»çÀÌÅäÄ«ÀÎ ¹× ¿°Áõ°ü·Ã¹°ÁúÀÇ ÆøÁõÀ¸·Î ¾ß±âµÇ´Â (TGF-1beta°æ·Î)CSS/ARDS, (TLR-4°æ·Î°ü·Ã)sepsis/MODSµîÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ°Ô µÊ... ±× Áß¿¡¼ antioxidant HO-1Àº (PKR-eIF2 °æ·ÎÈ°¼º°ú ÇÔ²²) ¹ÙÀÌ·¯½º»ç¸ê±âÀüÀ» ÇÔ²² ÁÖµµÇÏ°í Àֱ⿡ °¡Àå Áß¿ä......^^3)HO_1Àº ¹ÙÀÌ·¯½ºº¹Á¦ÀÇ ¸ðµç °úÁ¤À» ¾ïÁ¦½Ãų»Ó ¾Æ´Ï¶ó »ç¸êÀ» À¯µµÇÏ°í Àִµ¥, hemeÀ» »êÈÇÏ¿© biliverdin, CO, Fe2+·Î ºÐÇØÇÏ°í BVÀº ¹ÙÀÌ·¯½ºÆú¸®ÆéƼµåÀÇ ¼º¼÷À» Â÷´Ü, CO´Â NOX¾ïÁ¦°æ·Î·Î ROS»ý¼ºÂ÷´Ü, fe2+´Â ¹ÙÀÌ·¯½ºÀÇ RNApolymerase¸¦ Â÷´ÜÇÔÀ¸·Î½á °á±¹ ¹ÙÀÌ·¯½º»ç¸êÀ» À¯µµÇÏ°í ÀÖÀ½ ...¶ÇÇÑ, ¼¼Æ÷Áú³» PKRÀº nrf2È°¼º À¯µµÀÛ¿ë¿¡ ´õÇÏ¿© ¼ÒÆ÷ü(ER)¿¡ ÀÖ´Â PKR-À¯»ç kinaseÀÇ È°¼º °øÁ¶¸¦ ÅëÇØ eIF2(À¯ÇÙ¼¼Æ÷°³½ÃÀÎÀÚ)¸¦ ÀλêȽÃÅ´À¸·Î½á ¹ÙÀÌ·¯½ºpolymeraseÀÇ ¹ø¿ªÀ» ¾ïÁ¦ÇÏ¿© ¹ÙÀÌ·¯½ºÀÇ ºñ±¸Á¶´Ü¹é »ý»ê--genome º¹Á¦ ¹× viral mRNAÀü»ç/¹ø¿ª ÅëÇÑ ¹ÙÀÌ·¯½º ±¸Á¶´Ü¹é »ý»ê ¾ïÁ¦±îÁö ´ã´çÇÏ°í ÀÖÀ½
*¹ÙÀÌ·¯½º°¨¿°¿¡ ´ëÇÑ °¡Àå Áß¿äÇÑ ¼±Ãµ¸é¿ª¹ÝÀÀÀ¸·Î¼ ¼÷ÁÖ¼¼Æ÷ÀÇ IFN-1»ý»ê¹ÝÀÀÀº ÆÐÅÏÀνļö¿ëü(PRR)ÀÇ È°¼º ÅëÇØ ¹ß»ýµÊ.. RNA¹ÙÀÌ·¯½ºÀÇ °æ¿ì, ¹ÙÀÌ·¯½ºRNA¿Í RNApolymerase¸¦, retinoic acid inducible gene I (RIG-I)-like receptors°¡ ¸ÕÀú, ±×¸®°í °ð melanoma differentiation associated protein 5(MDAP5)°¡ °¨ÁöÇÏ°í mitochondrial antiviral-signaling protein (MAVS=IFN-beta promotor stimulator IPS-1)°ü·Ã ¸ðÁý¹ÝÀÀÀ» ÀÏÀ¸Å´.....ÇÑÆí, DNA¹ÙÀÌ·¯½ºÀÎ °æ¿ì, ¹ÙÀÌ·¯½º DNA´Â DEAD-box protein (DDX) 41, cyclic GMP-AMP synthase (cGAS), ¹× γ-IFN-inducible protein 16 (IFI16)¿¡ ÀÇÇØ °¨ÁöµÇ¸ç ÀÌ ¸ðµÎ´Â °á±¹stimulator of IFN genes (STING)ÀÇ È°¼ºÀ» À¯µµÇÔ ..... MAVS¸ðÁý ¹× STING È°¼ºÀº TANK-binding kinase 1 (TBK1)ÀÇ Ãß°¡¸ðÁý ¹× IRFÀÇ Àλêȸ¦ À̲ø¾î³»°í ÇÙÀ¸·Î À̵¿½ÃÄÑ IFNÁõ»ê¿¡ ÀÏÂ÷ÀûÀ¸·Î ¹ÝÀÀÇÏ´Â IFN regulatory factors (IRFs)ÀÇ Àü»çÈ°¼ºÀ» À¯µµÇÔ.... ¼¼Æ÷Áú³» RNA polymerase III ´Â ¿ÜºÎ¿¡¼ À¯ÀÔµÈ foreign and aberrant DNA¸¦ RNA·Î Àüȯ½ÃÅ°°í, RIG-1Àº RNAÀÇ 3ÁßÀλêÀ» °¨ÁöÇϱ⠶§¹®¿¡ RNA polymerase III´Â RIG-1°æ·Î ÅëÇØ ÀϾ´Â ¼±Ãµ¸é¿ª¹ÝÀÀÀ» °³½ÃÇÏ´Â DNA¼¾¼·Î ¿ªÇÒÀ» ÇÔ... Áõ»êµÈ IFNÀº ¼¼Æ÷¿¡¼ ºÐºñµÇ¾î IFNAR1 / 2¿¡ °áÇÕÇÏ¿© JAK / STAT È°¼ºÈ¸¦ À¯µµÇÏ°í È°¼ºÈ µÈ interferon stimulated geneÀÎ ISGF3 trimer ¶Ç´Â STAT1 dimer´Â ISRE ¶Ç´Â GAS ¼¿¿¡ °áÇÕÇÏ¿© ¾à300¿©°³ÀÇ ISGÀÇ ¹ßÇöÀ» ÃËÁøÇÔÀ¸·Î½á ¹ÙÀÌ·¯½ºµéÀ» ¾ïÁ¦ÇÔ....¹ÙÀÌ·¯½º´Â °¢ÀÚ ³ª¸§´ë·ÎÀÇ Æ¯ÀÌÇÑ ´ëó¹æ½ÄÀ» °³¹ßÇس»¾î ÀÎÅÍÆä·ÐÀÇ °ø°ÝÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇÏ°í ÀÖÀ½
*HSV´Â DNA¹ÙÀÌ·¯½º·Î¼ ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀº IFN-1ÀÌ ÃæºÐÇÒ ¶§ ´õ ¿Õ¼ºÇÑ Æ¯¼ºÀ» °¡Áö´Â ¹Ý¸é, COVID19´Â RNA¹ÙÀÌ·¯½ºÀε¥, ħ½À Ư¡Àº ³»Àμºnrf2 ÀúÇϸ¦ ÅëÇØ IFN-1 »ý»êºÐºñ ÀúÇÏ, ¹Ý¸é ¼¼Æ÷¸·ÀÇ ACE2Áõ°¡µÉ ¶§ ¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀÌ ¿Õ¼ºÇÏ°Ô µÇ´Â Â÷º°¼ºÀÌ ÀÖÀ½.....RNA¹ÙÀÌ·¯½º´Â ħ½ÀÃʱ⿡ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ³»Àμºnrf2ÇÏÇâÁ¶Àý, ÀÌ¿¡ µû¸¥ ¼¼Æ÷¸·ACE2Áõ°¡ ¹× IFN-1°¨¼Ò(¹ÙÀÌ·¯½ºÀÇ nucleocapsidÅ»°¢½ÅÈ£¿¡ µû¸¥ (IFN-1À» »ý»êÇÏ´Â)STING¹ÝÀÀ ¹ßÇöÀ» ÇÏÇâÁ¶ÀýµÈ nrf2°¡ °¨¼è ¹× Áö¿¬½ÃÅ´...±×·¯³ª, ÀÌ Çö»óÀº ¹ÙÀÌ·¯½ºgenomeº¹Á¦½ÃÁ¡ÀÌÈÄ autophagy³»¿¡¼ keap1ÀÌ Å»¶ôµÈ »óÅ·Π¼¼Æ÷Áú³»·Î À¯¸®µÈ free nrf2ÀÇ ÀÚ±ØÀ¸·Î ÀÎÇØ ±Øº¹ÀÌ µÇ´Âµ¥, ÀÌ ¶§´Â ¿ÀÈ÷·Á STINGÈ°¼º ¹× IRF3Àü»çÈ°¼ºÀ¸·Î ÀÎÇÑ IFN-1ÀÇ Áö¿¬¼º, °ú´ÙºÐºñÇö»óÀ» À¯¹ßÇÔ
=**¼¼Æ÷³» ³»Àμºnrf2 ÀÛ¿ëÀº Æò¼Ò¿¡´Â ¼¼Æ÷¸· ACE2¹ßÇö ¾ïÁ¦ + IFN-1»ý¼º°ü·Ã STINGÀü»ç¹ßÇö¾ïÁ¦ÇÔ(IFN-1Áõ°¡½Ã ¶Ç´Â nrf2È°¼ºÁõ°½Ã ¼¼Æ÷¸·ÀÇ ACE2¹ßÇöÀº °¨¼ÒÇÔ!!)....ACE2°ÅÃÄ ¼÷ÁÖ¼¼Æ÷³»·Î µé¾î¿Â ¹ÙÀÌ·¯½º nucleocapsid uncoating ¹× ¹ÙÀÌ·¯½º´Ü¹éÁõ»ê½ÅÈ£·Î ÀڱعÞÀº cGAS/STING¹ßÇöÀ» ³»Àμºnrf2´Â °¨¼è¹ÝÀÀÀ¸·Î °è¼Ó repressingÀ¯ÁöÇÔ (=±× °á°ú, IFN-1,3»ý»ê¾ïÁ¦, ¹Ý¸é¿¡ ACE2»ý»êÀº Áõ°¡)......¹ÙÀÌ·¯½ºgenomeº¹Á¦°¡ ¹ß»ýµÇ¸é¼ ºñ·Î¼Ò ¿ÀÅäÆÄÁö¿¡¼ ¼¼Æ÷Áú·Î À¯¸®µÈ free NRF2´Â of HO-1 »ý»êÇÏ¿© ±× °á°ú ^^¹ß»ýµÈ Fe2+´Â divalent metal-binding pocket of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV2¿¡ °áÇÕÇÏ¿© genomeº¹Á¦¸¦ ¾ïÁ¦((ºô¸®º£¸£µòÀº ±¸Á¶´Ü¹é ¼º¼÷ ¾ïÁ¦, fe2+´Â RNAº¹Á¦ Â÷´Ü, CO´Â NOX¾ïÁ¦ ÅëÇØ ROS¹ß»ýÂ÷´Ü)), ^^HO-1Àº ÀλêÈ°ÅÃÄ IRF3¿Í °áÇÕÇÏ¿© Àü»çµÊÀ¸·Î½á IFN-1»ý»êÀÌ Àç°³µÊ....ÇÑÆí, ¹ÙÀÌ·¯½º±¸Á¶´Ü¹é ¹ø¿ª´Ü°è¿¡¼´Â ¼÷ÁÖ¼¼Æ÷³»ÀÇ double-stranded RNA-activated protein kinase R (PKR)°¡ ÀÛµ¿µÇ¾î eIF2¸¦ ÀλêÈÇÔÀ¸·Î½á ¹ÙÀÌ·¯½º±¸Á¶´Ü¹é Áõ»ê ¾ïÁ¦ + PKRÀÛµ¿Àº p62¸¦ ÀλêȽÃÄѼ nrf2-keap1º¹ÇÕüÀÇ ¿ÀÅäÆÄÁö¸¦ ÃËÁø, À¯¸®nrf2¸¦ ¼¼Æ÷Áú³»·Î ¹æÃâ, nrf2È°¼ºÀ» º»°ÝÀç°³½ÃÅ´
=Nrf2È°¼ºÁ¦´Â ÁÖ·Î keap1ÀÌ nrf2¿¡ °áÇÕÇÏ´Â °ÍÀ» Â÷´ÜÇϰųª nrf2-keap1º¹ÇÕü·ÎºÎÅÍ keap1Å»¶ôÀ» À¯µµÇÔÀ¸·Î½á nrf2È°¼ºÀ» ÃËÁø½ÃÅ´....³»Àμº Ç×»êÈÁ¦ »ý»ê ÃËÁø ¹× Th1°æ·Î¾ïÁ¦/Th2°æ·Î È°¼º, NFkBÀü»çÂ÷´Ü ÅëÇØ Ç׿°ÀÛ¿ëÀ» ³ªÅ¸³¿À¸·Î½á ´Ù¾çÇÑ ¸¸¼º¿°ÁõÁúȯġ·áÁ¦·Î »ç¿ë°¡´É ....´õºÒ¾î sirt1 È°¼ºÁ¦´Â innate immunity°ü·Ã Th-17AÂ÷´Ü(ÀÚ°¡¸é¿ªÁúȯ Ä¡·á), Ÿ°ÙÀ¯ÀüÀÚ¿¡¼ NFkBÀü»çÂ÷´ÜÀÛ¿ëÀ» ³ªÅ¸³¿.
-----------
===¾ÏÁٱ⼼Æ÷½ÅÈ£3ÃÑ»ç : Wnt, Hedgehog, Notch --À̵éÀÌ »ó½Â½Ã ¾Ï¹ß»ý ÃËÁø..==>¾ÏÁٱ⼼Æ÷ Ç¥Àû »ç¸ê È¿°ú°¡ ÀÔÁõµÈ ¿µ¾ç¼Ò ¹× ÇÇÅäÄɹÌÄ®µé·Î¼´Â. vit.D3, EGCG. Sulforaphan, Curcumin, Piperine. Silibin (Silibin30mgÀº Silymarin70mg¿¡ ÇÊÀû). ±× ¿Ü>Á¦´Ï½ºÅ×ÀÎ, ·¹½ºº£¶óÆ®·Ñ, Äõ¼¼Æ¾, DIM, Æĸ£Å׳î¶óÀ̵å(¿©¸§Èò±¹ÈÀÙÃßÃâ¹°)
==ÀÏÁ¾ÀÇ STING disorder°¡ Ư¡ÀÎ COVID19°¨¿°¿¡¼ Nrf2 activator »ç¿ë±Ù°Å :[[NRF2 activatorÀÇ COVID19 ¼¼Æ÷³»Ä§½À ¾ïÁ¦, º¹Á¦ ¾ïÁ¦/ų¸µ À¯µµ, ¿°Áõ ÆøÁõ/»çÀÌÅäÄ«ÀνºÅè-ARDS ¹× MODS µî ÇÕº´Áõ ¾ïÁ¦ ¸ñÀû]]
.....COVID-19´Â Á¦ÀÏ ¸ÕÀú ü³»/¼¼Æ÷³» NRF2¸¦ ¾ïÁ¦ÇÔ(ȯÀÚÀÇ Æó »ý°Ë°üÂû°á°ú NRF2 °æ·Î ¾ïÁ¦ -->¼¼Æ÷¸·ÀÇ ACE2»óÇâÁ¶Àý À¯µµ), ¶ÇÇÑ, Nrf2 activatorÅõ¿©´Â SARS-CoV2ÀÇ º¹Á¦¿Í ¿°Áõ ¹ÝÀÀ ÁõÆøÀ» ¾ïÁ¦ÇÔ----±× »ó¼¼±âÀüµéÀº
**Nrf2È°¼º ÅëÇØ ¼¼Æ÷¸·ÀÇ ACE2Á÷Á¢ ÇÏÇâÁ¶Àý(¹ÙÀÌ·¯½ºÄ§ÀÔ Â÷´Ü)
**1Çü IFN ÇÏÇâÁ¶Àý(IFN-1ÀÇ Áö¿¬¼º°ú´ÙºÐºñ + NFkBÈ°¼º°ú´Ù·Î ¾ß±âµÇ´Â »çÀÌÅäÄ«ÀνºÅè ¹æÁö :: ¹ÙÀÌ·¯½º°¡ ¾ß±âÇÑ IFNÀ¯ÀüÀÚÀÚ±Øü(STING)ÀÇ È°¼ºÅëÇÑ IRF3»ý¼º-1ÇüIFNÀÇ Áö¿¬¼º °ú´Ù»ý»ê ±âÀüÀÇ Â÷´Ü ÅëÇØ)
**HO-1È°¼ºÀ¯µµ(HO-1Àº hemeÀ» biliverdin, fe++, CO·Î ºÐÇØ :: ºô¸®º£¸£µòÀº viral ÇÁ·ÎÅ×¾ÆÁ¦¸¦ ºÐÇØ, fe++´Â ¹ÙÀÌ·¯½ºº¹Á¦ Â÷´Ü, CO´Â ÀÌÂ÷ÀûÀÎ ROS»ý¼º-¿°Áõ ¹ß»ý¾ÇÈ Â÷´Ü..fe++¿ÍCO´Â NFkB¾ïÁ¦),
**¹«³ÊÁø REDOX Ç×»ó¼ºÀ» ȸº¹½ÃÅ´
**NRF2ÀÇ ÀλêÈ ÅëÇØ ER¿¡¼ free pERKÀÚ±Ø ÅëÇØ ¹ÙÀÌ·¯½º mRNA¹× ±¸Á¶¹° º¹Á¦ÀÇ ¸ðµç °úÁ¤¸¶´ÙÀÇ ½ºÀ§Ä¡ ¿ÀÇÁ(pERK.[ER¿¡ À§Ä¡ÇÑProtein KinaseR-À¯»ç kinase]´Â eIF2[À¯ÇÙ¼¼Æ÷°³½ÃÀÎÀÚ]ÀÇ Àλêȸ¦ À¯µµ, ÀÌ p-eIF2°¡ ¹ÙÀÌ·¯½ºÁßÇÕÈ¿¼ÒÀÇ Àü»ç¸¦ Â÷´Ü + ¹ÙÀÌ·¯½ºÀ¯ÀüÀÚ º¹Á¦ Â÷´Ü + ¹ÙÀÌ·¯½º mRNA Â÷´ÜÇÔÀ¸·Î½á ´Þ¼º)
==[[Ç׳ëÈ = °á±¹ Ç׿°ÀÛ¿ë ¹× ¿°Áõ°³¼±ÀÌ Áß¿ä]] p38MAPK-->COX2, NFkB-->COX2 °æ·Î ÀÌÁßÈ°¼º°á°ú ¿°Áõ¹°ÁúÀÌ °ú´Ù»ý¼ºµÇ°í, ÀÌ·Î ÀÎÇÑ Àü½Å±â°ü ³ëÈ ¹× ºÎ½ÅÀÇ ¼ºÈ£¸£¸ó»ý»ê°¨¼Ò·Î ¼º±â´ÉÀÌ»ó À¯¹ßµÊ
===========
**AREÀü»ç°á°ú »ý»ê´Ü¹éÁúµé : NQO1(.ȯ¿ø/Á¦µ¶), HO-1(Ç×»êÈ, Ç׿°, Á¦±Õ), UDP-GT(¾àÁ¦/µ¶¼Ò Á¦µ¶ ¹× ¹èÃâ), Mrps(¾àÁ¦³»¼º), SRXN1/TXNRD1(°ú»êȼö¼Ò/Áú¼Ò»êȹ° Á¦°Å), GCLC/GCLM(GSH»ý»ê), glutathione S-transferase(Á¦µ¶ÈÄ GSHÀç»ý)
-----------
[[NAD+-dependent deacetylaseÀÎ SIRT1 ¼¼Æ÷ ½ÅÈ£ Àü´Þ °æ·Î....SIRT1/ AMPK / PGC-1 α °æ·Î Ÿ°ÙÆÃ....SIRT1 activatorsÀåÁ¡]]
**1)AMPK(AMP-activated protein kinase)È°¼º ÃËÁø½ÅÈ£ : »êȽºÆ®·¹½º ¹× LKB1(Ser-Thr liver kinase B1 : sirt1ÀÇ »ó´ëÀû ºÎÁ·À» °¨ÁöÇÏ°í ÀÛµ¿µÊ...AMPK°æ·Î ÀÚ±Øü )ÀÚ±ØÀ¸·Î AMPK´Â È°¼ºµÇ¾î ¹ÌÅäÄܵ帮¾Æ »ý»êÁõ°¡+Áö¹æ»ê»êÈ+Àν¶¸°¹Î°¨µµ »óÇâÁ¶ÀýÀ¯µµ
**2)NAD+/NADHºñÀ² »óÇâ ½ÅÈ£
**3)SIRT1 È°¼º½ÅÈ£ :
^AMPK»óÇâÁ¶ÀýÀ¯µµ½ÅÈ£µéÀÌ Áß¿äÇѵ¥, NAD+/NADH ºñÀ² »óÇâ½ÃÅ´À¸·Î½á ¹ß»ýÇÏ´Â ½ÅÈ£ ¹× DNA¼Õ»ó ½ÅÈ£´Â SIRT1 È°¼ºÀ» ÀÚ±ØÇÔ, ¶ÇÇÑ ¶§¶§·Î »êȽºÆ®·¹½ºÀÚü°¡ SIRT1»ý»êÀ» ÀÚ±ØÇÔÀ¸·Î½á SIRT1»óÇâÁ¶ÀýÀÌ ¹ß»ý, ±× °á°ú LKB1Å»¾Æ¼¼Æ¿È ÅëÇØ AMPK¸¦ È°¼º½ÃÅ°°í NAD+/NADH ºñÀ²À» ÀúÇϽÃÅ°´Â ¾ç¼ºÇǵå¹éÁ¶Àý°è¸¦ Çü¼ºÇÔ, ±âŸ SIRT1 È°¼º°ü·Ã±âÁ¦µéÀ» º¸¸é..
^SIRT1È°¼º°á°ú, PPAR-gamma coactivator-1alpha(PGC-1α)ÀÚ±Ø..[±×°á°ú ¹ÌÅä.»ý»êÃËÁø+ÁöÁúÆ÷µµ´ç Ç×»ó¼º À¯Áö+Ç×»êȹæ¾î·ÂÀ¯Áö¿¡ °ü¿©..PGC1a´Â nrf1, nrf2ÀÇ È°¼º°øÁ¶ÀÚÀÌ¸é¼ µ¿½Ã¿¡ ¹ÌÅä.»ý»ê +´çºÐ/ÁöÁú ºÐÇØ ÀÌ¿ëÀÇ ÁÖ¿äÁ¶ÀýÀÚÀÓ...Ç×»êÈÁ¶ÀýÀº nrf2, FOXO3a, PGC1apha¿¡ ´ëÇÑ SIRT1È°¼º°á°úÀ̸ç ƯÈ÷ FOXO3a¿Í PGC1alphaÀÇ Å»¾Æ¼¼Æ¿È °ÅÃÄ ÀÌ·ç´Â º¹ÇÕü´Â MnSOD.CAT¸¦ Áõ»ê½ÃÅ´...NAFLD¹× hepatic steatosis½Ã SIRT1 activatorsÀÎ ·¹½ºº£¶óÆ®·Ñ/Äõ¼¼Æ¾ ¹× ¾ËÆĸ®Æ÷ÀÍ»êÀ» Åõ¿©ÇÏ´Â ±Ù°Å´Â cAMP-PRKA-AMPK-SIRT-PGC1alpha½ÅÈ£°æ·ÎÈ°¼º½ÃÅ´À¸·Î½á ÀϾ´Â Áö¹æ»ê»êÈÀ¯µµ ¹× ¿ÀÅäÆÄÁö ¹× Ç×»êȹ°Áú»ý»êÀÛ¿ëÀ» ÅëÇØ °³¼±½ÃÅ°±â ¶§¹®ÀÓ...¼ÒÈÀå¾Ö¿¡ À־µ SIRT1Àº µ¿ÀÏÇÑ ±âÀüÀ¸·Î ÀÛµ¿µÈ´Ù°í ¿©°ÜÁü],
^p53À» ¾ïÁ¦..[±× °á°ú ¾Ï¹ß»ý¾ïÁ¦ + ¼¼Æ÷ÀÚ»ìÁ¶ÀýÀ» ¼öÇà...°£¾ÏÁٱ⼼Æ÷´Ü°è¿¡¼´Â »ó½ÂµÇ¾ú´ø SIRT1Àº ¾ÏÁٱ⼼Æ÷ÀÇ ºÐÈ°úÁ¤¿¡¼´Â ÀúÇϵǴ Çö»óÀ» º¸À̸ç, ¿ÜºÎ¿¡¼ SIRT1È°¼ºÁ¦Åõ¿©·Î ÀÎÇÑ SIRT1°ú¹ßÇöÀº ¾ÏÁٱ⼼Æ÷°¡ ¾Æ´Ñ ¾Ï¼¼Æ÷µéÀÇ self-renewalÀ» ȸº¹½ÃÅ°¸ç ÀÌ °úÁ¤¿¡ °ü¿©ÇÏ´Â Á¶ÀýÀÚ´Â SOX2¶ó´Â °ÍÀÌ ¹àÇôÁ®¼ HCCÄ¡·á¿¡ SIRT1È°¼ºÁ¦¸¦ Åõ¿©ÇÏ´Â ±Ù°Å°¡ µÊ],
^NFkB¸¦ ¾ïÁ¦..[¼¼Æ÷ÇÙÀ¯ÀüÀÚºÎÀ§¿¡¼ Àü»çÂ÷´Ü°úÁ¤À¸·Î ¿°ÁõÁ¶Àý...THF-alpha, IL-1β, and IL-6 µî proinflamm.cytokines Àü»ç¹ßÇö ¾ïÁ¦..histones, transcription factors NF-kB and AP-1 µîÀ» Å»¾Æ¼¼Æ¿È...IBDÄ¡·á¿¡ Áß¿ä .],
^UCP2(uncoupling protein2gene) Àç¾ïÁ¦.. [SIRT1Àº ÃéÀ庣Ÿ¼¼Æ÷¿¡¼ ¿ø·¡ E2F1Àü»çÈ°¼ºÀ» ¾ïÁ¦ÇÏÁö¸¸, E2F1ÀúÇÏ´Â SIRT1¹ßÇöÀ» ¿ÀÈ÷·Á »óÇâÁ¶ÀýÇÔ, ¹Ý¸é¿¡ SIRT1È°¼ºÀº Àν¶¸°ºÐºñ¸¦ ¾ïÁ¦(±×·Î ÀÎÇØ ¿»ý¼ºÁõ°¡, ÁöÁúÃàÀû, ºñ¸¸À¯µµ)ÇÏ°í ÀÖ´Â UCP2¸¦ Àç¾ïÁ¦ÇÔÀ¸·Î½á Àν¶¸°ºÐºñ ÃËÁø/¹Î°¨µµ Çâ»ó]
**[[Regeneration and Aging: Regulation by Sirtuins and the NAD+ Salvage Pathway]]
°íÁö¹æ½ÄÀÌ ¼·Ãë½Ã´Â NAD+¼Ò¸ð Áõ´ë, °á°úÀû °¨¼Ò°¡ À¯¹ßµÇ¾î (´ç´¢º´¼º ¸»ÃʽŰ濰¿¡¼ º¸µí) »êÈÀλêÈÀÇ ÀúÇÏ-ÁöÁúÃàÀû-½Å°æaxon¼Õ»óÀÌ À¯¹ßµÇ´Âµ¥, ´ÏÄÚƾ¾Æ¹Ìµå¸ð³ë´ºÅ¬·¹¿ÀƼµå((³ªÀ̾ƽžƹ̵å, ´ÏÄÚƾ¾Æ¹Ìµå))¸¦ Åõ¿©ÇÏ¸é °íÁö¹æ½ÄÀÌÁß´Ü ¾øÀ̵µ ¿ªÀ¸·Î NAD+°¡ Áõ»êµÇ¾î »êÈÀλêÈ È¸º¹-ÁöÁúÃàÀû ÇؼÒ-½Å°æÃà»è ¼Õ»óȸº¹À» º¼ ¼ö ÀÖ¿È ======vitamin D °ø±Þ½Ã SIRT1, irisin, BDNF Áõ»ê + IR °³¼±(ºñ¸¸ 2ÇüDM)======
**[[COVID19+INFLUENZA twindemic ]] 1Çü ÀÎÅÍÆä·Ð Áõ»ê±îÁö °í·ÁÇÑ ¹æÃ¥.
>>°¨¿°È®ÁøÀÚ ::: ÇǶó¸Æ½º 3ÀÏ¿ä¹ý ¶Ç´Â ´ÙÀ½ÀÇ combination therapy 5ÀÏ¿ä¹ý---- ¾ÈÅä½Ã¾È 1000mg#2(for IFN-1) + HCQ 800mg #2 + artemisinin 800mg #2 + bromelain 200mg #2 + EGCG/curcumin/ silymarin/ sulforaphan/piperine 4T #2 (for SIRT1 activator and nrf2 activator ::: act-N)...±× ÀÌÈÄ ¿¹¹æ¿ä¹ýÀ¸·Î º¹±Í
>>°¨¿°¿¹¹æ : (ÁÖ1ȸ ÇǶó¸Æ½º.. 3ÁÖ°£ ÈÄ 1 ÁÖ ÈÞ¾à) ¶Ç´Â (ÁÖ1ȸl)HCQ 400mg + (¸ÅÀÏ1ȸ) ¾Æ¸£Å×¹Ì½Ã´Ñ 100mg + ¼¿·¹´½200mcg, ¾Æ¿¬50mg VD5000 IU + tumeric400mg or Quercetin400mg // bromelain 100mg +¾ÈÅä½Ã¾È 170mg + ¾ËÆĸ®Æ÷»ê600mg..¹Ù½ºÆ¼³¿¥¾Ë35mg ¸ÞÆ®Æ÷¸£¹Î500mg
===================
[[1ÇüIFN Áõ»ê+ SIRT1È°¼º+nrf2È°¼º((Ç×¾Ï-Ç׳ëÈ-Ç׿°-ÇнÀ/±â¾ïÁõÁø-È°·ÂÁõÁø +¹ÙÀÌ·¯½º°¨¿° ¿¹¹æ ¹× ¹Ú¸ê))]]=10+9.....Æ®¸®¸ÞŸÁöµò-¸ÞÆ®Æ÷¸£¹Î-¸®Æ÷»ê-¾ÈÅä½Ã¾È-Ÿ³ª¹Î-ºê·Î¸á¸°-¿£Å×·Ð-SAMe-HCQ-VD + VC-B3-Zn-Se-MSM-¾ËÅ׹̽ôÑ-Ä¿Å¥¹ÎorÄõ¼¼Æ¾-¾Æ½ºÅ¸»êÄ£/·çÅ×ÀÎ
====respiratory burst : NAD(P)H+2O -->NAD(P)+, 2O2-, H+=======
NADPH ¹× NADH´Â ¸Å¿ì °·ÂÇÑ ÀüÀÚ°ø¿©Ã¼·Î¼ ÀλêÈÀüÀÌÈ¿¼Ò³ª oxidase¿¡ ÀÇÇØ »êÈ µÇ¾î °¢°¢ NAD+ ³ª NADP+ °¡ µÇ¸é¼ ÀüÀÚ e-¿Í ¼ö¼ÒÀÌ¿Â H+¸¦ ³»¾îÁÜÀ¸·Î½á ¼¼Æ÷¿¡ ȯ¿ø·ÂÀ» Á¦°øÇÏ°í ÀÖÀ½( »êÈ °á°ú ROS ¹ß»ýµÊ).......¹Ù·Î ÀÌ NAD+¸¦ ±âÁ¦·Î »ç¿ëÇؼ ¾ÈÁ¤µÈ »óÅÂ(¾Æ¼¼Æ¿È»óÅÂ)¿¡ ÀÖ´Â ±âÁ¦(¿¹ :PGC1alpha)ÀÇ Å»¾Æ¼¼Æ¿È¸¦ À¯¹ß½ÃÄѼ È°¼º»óÅ·Π¸¸µé¾î ÀÛµ¿µÇµµ·Ï ¸¸µå´Â °ÍÀÌ SIRT1ÀÌ ÇÏ´Â ÀÏÀÓ.....ÀÎü´Â ȯ¿ø·Â Á¦°øÀ» À§ÇØ ÁÖ·Î NADH¸¦ »ç¿ëÇÏ°í ÀÖÀ¸³ª(SIRT1 È°¼ºÁ¦·Î ÀÛµ¿ÇÏ´Â niacinamide(NAM)´Â NAMPT(NAMÀλêÈÀüÀÌÈ¿¼Ò)¸¦ ÀÛµ¿½ÃÄѼ NADH·Î ºÎÅÍ NAD+¸¦ Áõ»êÇÏ¿© SIRT1È°¼º±âÁ¦·Î Á¦°øÇÏ°í ÀÖÀ½) ....½Ä¹°Àº ±¤ÇÕ¼º¿¡ ȯ¿ø·ÂÀ» Á¦°øÇÔ¿¡ ÀÖ¾î¼ NADPH¸¦ »ç¿ëÇÏ°í ÀÖ´Â ¹Ù, NADPH¸¦ »êÈÇÏ´Â .NADPH oxidase µé(NOXs) Áß [¹°·Ð NOX1, NOX4 ¾ïÁ¦½Ãų ¶§¿¡µµ ROS¼Ò°Å°¡ È®Àεǰí ÀÖÀ¸¸ç, IFN-alpha, beta,gamma»ý»ê Áõ°¡°¡ µ¿¹ÝÇÑ´Ù°í º¸Áö¸¸] ƯÈ÷ NOX(NOX2)¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϸé(±×°á°ú ROS ¼Ò°Å°¡ ¼ö¹ÝµÊ) 1Çü ÀÎÅÍÆä·Ð(¾ËÆÄ, º£Å¸ IFN)ÀÌ À¯µµµÊÀÌ È®ÀεǾî ÀÖÀ½......Áï, NOX2 inhibitorµéÀº 1Çü ÀÎÅÍÆä·Ð À¯µµÁ¦(IFN-1 inducer)¿ªÇÒÀ» ÇÔ.......[È®Á¤µÈ]´ëÇ¥ÀûÀÎ NOX2 inhibitors´Â trimetazidine, sulforaphan, ºñŸ¹Î B3, ºñŸ¹ÎD, alpha-lipoic acid antocyanine of elderberry, berberine, beta-sitosterol, curcumin, quercetine, ficetine,µîÀÌ ÀÖÀ½ (^À°Á¾¿ëÃßÃâ¹°/beta-sitosterol :SIRT1 activator + nrf2 activator + NOX2inhibior/IFN-1inducer).....Natural Compounds as Modulators of NADPH Oxidases
------------------
ALa/Vast/metf/sily-tana/ente/brom/NAC-SAMe/HCQ [[VD.VB2,B3.Zn.Se.curcu]]
----------------
***TGF-1beta inhibitor (¼¶À¯È ¾ïÁ¦ local/systemic fibrosis, ARDS¾ïÁ¦)...NAC..±Û¸®½Ã¸®Áø, Ä¿Å¥¹Î..EGCGµµ µ¿ÀÏÈ¿°ú): TGF1beta-CCN1 TGFβ1 À¯µµ CCN1 ¹× ET-1, α-SMA mRNA ¹ßÇöÀ» ¾ïÁ¦
***TLR4 inhibitor( DAMP response ¹× STINGÀå¾Ö¾ïÁ¦ -- sepsis, MODS¾ïÁ¦)..Ä¿Å¥¹Î, ¼³Æ÷¶óÆÇ
**ACTn-tume/brom-MSM/ART-ZnSeD[[SIRT1activator-Nrf2activator--NOX2inhibitionORnot]]The Effect of N-Acetylcysteine on RespiratoryEnzymes, ADP/ATP Ratio, Glutathione Metabolism,and Nitrosative Stress in the Salivary GlandMitochondria of Insulin Resistant Rats
============
@@@ NRF2 activatorÅõ¿©½Ã ±â´ëÇÒ ¼ö ÀÖ´Â ¹Ù, ARE À¯ÀüÀÚÀü»ç ÅëÇÑ nrf2°æ·ÎÈ°¼ºÀÇ Á÷Á¢È¿°ú
[nrf2È°¼ºÀÚ±ØÃËÁø¿ä¼Òµé-»ó·ù] oxidative stress, metabolic stress, oncogenic stress
**oxidative stress : (³»Àμº)¹ÌÅäÄܵ帮¾Æ »êÈÀλêÈ°úÁ¤»ê¹°, p450´ë»ç»ê¹°, peroxisome´ë»ç»ê¹°, ¿°Áõ¼¼Æ÷È°¼ºÈ»ê¹° (¿ÜÀμº)xenobiotics, ¿°¼ÒÈÇÕ¹°, ¹æ»ç¼±, °¨¿°º´¿ø, ¿°Áõ¼º»çÀÌÅäÄ«Àεé..ÀÏÂ÷»ê¹°Àº superoxide anion..
^^SOD(O2-,superoxide anion --> H2O2),==> Catalase/GPx(H2O2--->H2O+O2)
[nrf2°æ·Î È°¼º°á°ú ¼¼Æ÷º¸È£±â´É ¹ßÇö Áõ»ê¹°-ÇÏ·ù]] :::2»ó Çص¶È¿¼Òµé(´ëÇ¥::NQO1, GST, UGT) ¹× Ç×»êÈÈ¿¼ÒµéÀ» »ý»ê. cf>*Çص¶/Á¦µ¶ Á¦1»ó(phase I) :¿ÜºÎÅõ¿©ÈÇÕ¹°(xenobiotic)ÀÌ CYP1,2,3,4ÀÇ ÀÛ¿ë °ÅÃÄ non-electrophilic ¶Ç´Â reactive electrophiic ´ë»ç¹°(¹ÝÀÀ¼º, ÀüÀÚģȼº´ë»ç¹° ±×´ë·Î´Â µ¶¼º»óÅÂ, À¯ÀüÀÚº¯Çü ¹× ¹ß¾Ï À¯¹ß °¡´É)·Î Àüȯ...±×ÈÄ¿¡ ¼ö¹ÝµÇ´Â ¹«µ¶È°úÁ¤ÀÌ Çص¶/Á¦µ¶ Á¦2»ó(phase II)
--¾à¹°, µ¶¼ÒµéÀÇ Á¦µ¶/ROSÀÇ Ç×»êÈ--
**NQO1 :: NAD(P)H quinone oxidoreductase1 : »êÈ/ȯ¿ø¹ÝÀÀ ¹× »êȽºÆ®·¹½º¸¦ À¯¹ßÇÏ´Â °íÈ°¼ºquinoneÀÇ È¯¿ø/Á¦µ¶ ´ã´ç
**GST :: Glutathione S-transferase : ¼¼Æ÷Áú-¹ÌÅäÄܵ帮¾Æ, ¹ÌÅ©·Î¼Ø¿¡¼ GSH¿¡ °áÇÕµÈ ³»Àμº/¿ÜÀμºµ¶¼º ´ë»ç¹°ÀÇ ÀüÀÚ ÁßÇÕü¸¦ ºÐÇØ/Á¦µ¶ ´ã´ç
**UGT :: UDP-glucuronosyltransferase : glucurinidationÅëÇØ Áö¿ë¼ºµ¶¼Ò¸¦ ¼ö¿ë¼ºÀ¸·Î º¯È¯
**thioredoxin (TXN1, PRDX1, TXNRD1, and SRXN1) : °íÈ°¼ºperoxide(H2O2 ¹× peroxynitrite)ÀÇÁ¦µ¶À» ´ã´çÇÏ´Â peroxyredoxinÀ» º¸Á¶ÇÏ´Â ¿ªÇÒ
**Glutathione ÇÕ¼ºÈ¿¼Ò (GCLC/GCLMÀº GSH»ý»êÀÇ rate-limiting step, ±× ¿Ü¿¡ GSR, GPX2, and SLC7A11),
**Mrps ::´ÙÁß¾àÁ¦³»¼º multidrug resistance–associated proteins (ABCC1 and ABCC2), ¼¼Æ÷¸·¼ººÐÀ¸·Î¼ ´ãÁó-Ç÷Àå³»·Î µ¶¼º´ë»ç»ê¹°µéÀ» ¹èÃâ Á¦°Å
--¼¼Æ÷ȯ¿ø´ÉÁõ´ë--
**NADPHÀç»ý»ê(G6PD, PGD, ME1, IDH1)ÅëÇÑ ¼¼Æ÷ÀÇ È¯¿ø´É Áõ´ë : G6PD ¹× PGD´Â Æ÷µµ´çÀÇÁ¸¼ºpentose phosphate pathway È¿¼Òµé, ME1 and IDH1´Â central carbon metabolism°ü·ÃÈ¿¼Òµé
--iron/heme Ç×»ó¼ºÀ¯Áö--
**Iron´ë»ç(HO-1, ÈѸ®Æ¾ heavy chain/light chain°ü·ÃÀ¯ÀüÀÚ FTL1/FTH1) : iron/heme Ç×»ó¼ºÀ¯Áö,
^±ÔÄ¢Àû¼¼Æ÷ÀÚ»ìapoptosis°ú´Â À¯ÀüÀû-»ýÈÇÐÀûÀ¸·Î ºÐ¸íÈ÷ ´Ù¸¥ ¼¼Æ÷ÀÚ¸êÇÁ·Î±×·¥À¸·Î¼ ¼¼Æ÷³» °ú»êÈÁöÁú°ú öºÐÃàÀûÀ¸·Î ¾ß±âµÇ´Â öºÐÀÇÁ¸¼º ¼¼Æ÷»ç¸êÀÎ ferroptosis(±× °á°ú, ¾Ï-½Å°æÅðÇàÁúȯ-½ÉÇ÷°üÁúȯ À¯¹ß), ÀÌ°ÍÀ» Â÷´Ü
^HO-1..hemeÀ» ºÐÇØÇÏ¿© Ç×»êȹ°Áú biliverdin, Ç׿°¹°ÁúÀÎ Fe++¿Í CO(NFkB¾ïÁ¦)·Î ºÐÇصǾî, ¼¼±Õ/¹ÙÀÌ·¯½ºÀÇ Áõ½ÄÀÇ ´Ü°èº° Â÷´Ü ÅëÇØ sepsis ¹ß»ý ¾ïÁ¦, °íÇ÷¾Ð-µ¿¸Æ°æÈ-±Þ¼ºÆó/½ÅÀå¼Õ»ó, °ÝÅë ¹ß»ý ¹× ¾Çȸ¦ Â÷´Ü.
=====[[¾Ï¿¹¹æ ¹× Ä¡·á +COVID19¿¹¹æ : õ¿¬¹°...À̵éÀº SIRT1È°¼ºÁ¦µé]]====
**mTOR´Â ¼¼Æ÷³»´Ü¹éÁúÁõ»ê-¼¼Æ÷¼ºÀå°úÁ¤À» ÀÚ±Ø(¼¼Æ÷ºÐ¿°¡´ÉȽ¼ö´Â ¼¼Æ÷¸¶´Ù ±× ÇÑ°è°¡ ÀÖ°í ±× ÇѰ踦 ³Ñ¾î¼¸é ¼¼Æ÷ÀÚ»ìÀÌ ÀϾ!!)//¿ÜºÎ½ºÆ®·¹½ºÀڱصéÀº °á±¹ mTOR¸¦ ¾ïÁ¦ÇÏ¿© ¼¼Æ÷Áõ½Ä¾ïÁ¦=»ýü¼ö¸í¿¬ÀåÀ» ²ÒÇÔ... SIRT1È°¼ºÁ¦µéÀº SIRT1È°¼ºÀÚ±Ø -->(mTOR¸¦ ¾ïÁ¦Á¶ÀýÇÏ´Â) Tuberin= TuberousSclerosisComplex2(TSC2)¸¦ È°¼ºÀÚ±Ø==>mTOR¸¦ ¾ïÁ¦Á¶Àý :: ¼ö¸í¿¬Àå-Ç׳ëȹÝÀÀ À¯µµ
** PI3K/Akt/mTOR °æ·ÎÀÇ Á¶ÀýÀå¾Ö°¡ Ư¡ÀÎ ¾Ï¼¼Æ÷´Â Á¤»ó¼¼Æ÷¿Í ºñ±³ÇØ º¼ ¶§ PI3K/Akt/mTOR ¾ïÁ¦Á¦¿¡ ´õ ¿¹¹ÎÇÏ°Ô ¹ÝÀÀÇÔÀ¸·Î½á ¾Ï¿¹¹æ ¹× ÁøÇ༺ ¾ÏÄ¡·á¿¡ µµ¿òµÊ
::: ÀÌ¿¡ ÇØ´çµÇ´Â õ¿¬ºÒÁú·Î¼´Â Ä¿Å¥¹Î[°È²]--DIM[ºê·ÎÄݸ®/Äݸ®Çöó¿ö]--EGCG/Ä«ÆäÀÎ[³ìÂ÷/Ä¿ÇÇ]--VE, Äõ¼¼Æ¾[¾çÆÄ/Â÷/Æ÷µµ/»ç°ú]--ÇǼ¼Æ¾[µþ±â/»ç°ú/°¨/¾çÆÄ], ¾ÆÇÇ°Ô´Ñ[»ç°ú/¿À·»Áö/ü¸®/Æ÷µµ], ·¹½ºº£¶óÆ®·Ñ[ÀûÆ÷µµ/ÀûÆ÷µµÁÖ]--¼¿¶ó½ºÆ®·Ñ, À̼ÒÇöóº», Å©¸³Åäź½Ã³í........ÇÑÆí, .COVID19¿¹¹æÈ¿°ú°¡ ÀÔÁõµÈ ½Ä¹°·Î¼´Â :: »ý°/½ÉȲ/¸¶´Ã/¾çÆÄ/°èÇÇ/·¹¸ó/´Ô/¹ÙÁú/¾à¿ë¹ö¼¸/ÆÄÆľßÀÙ ((ºñŸ¹ÎD°¡ Æ÷ÇÔµÊ))
@Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
@Natural products as home‐based prophylactic and symptom management agents in the setting of COVID‐19
@Phytochemicals and PI3K Inhibitors in Cancer—An Insight :::: PI3K/AKT/mTOR, NF-kB, autophagy, MEK-ERK, inflammation, oxidative stress and apoptosis.
@All About mTOR + Natural mTOR Inhibitors & Activators
@Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
===´º·ÎÇʸ°-1Àº VEGF-A¿Í °øÅë¼ö¿ëü·Î ÀÛµ¿µÊ==
^^^NRP1¿¡ ´ëÇÑ VEGF °áÇÕÀº ³»ÇÇ ¼¼Æ÷ À̵¿ÀÇ VEGF ÀÚ±Ø, NRP1°ú VEGFR2 °£ÀÇ º¹ÇÕü Çü¼º ¹× FAK Tyr407 Àλêȸ¦ ÅëÇÑ ½ÅÈ£ Àü´Þ¿¡ ÇʼöÀû.....³»ÇÇ ¼¼Æ÷¿¡¼ ´º·Î Çʸ° -1 (NRP1)Àº Ç÷°ü ³»ÇÇ ¼ºÀå ÀÎÀÚ (VEGF) -A¿¡ °áÇÕÇÏ°í KDR°ú °áÇÕÇÏ°í VEGF ½ÅÈ£¸¦ °ÈÇÏ¿© Å°³ªÁ¦ »ðÀÔ µµ¸ÞÀÎ ÇÔÀ¯ ¼ö¿ëü (KDR)¿¡ ´ëÇÑ ÄÚ¾î ¼ö¿ëü ¿ªÇÒÀ»ÇÏ´Â °Í...VEGF ¶Ç´Â VEGF-A´Â Ç÷°ü »ý¼º ¹× Ç÷°ü »ý¼ºÀ» ÀÚ±ØÇÏ´Â Ç÷°ü ³»ÇÇ ¼¼Æ÷¿¡ ´ëÇÑ Æ¯Á¤ À¯»ç ºÐ¿Ã¼ÀÓ
...VEGF´Â Ƽ·Î½Å Å°³ªÁ¦ ¼ö¿ëü, VEGFR1 ¹× VEGFR2 (Å°³ªÁ¦ »ðÀÔ µµ¸ÞÀÎ ÇÔÀ¯ ¼ö¿ëü, KDR)¸¦ ÅëÇØ ÀÛ¿ë. ƯÈ÷, KDRÀº »ýÁ¸, Áõ½Ä, À̵¿, Ç÷°ü Åõ°ú¼º, ¼¼´¢°ü »ý¼º, NO ¹× ÇÁ·Î ½ºÅ¸³ëÀÌµå »ýÇÕ¼º, À¯ÀüÀÚ ¹ßÇöÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ »ý¸®Àû ±â´ÉÀ» °¡Áø ¿©·¯ °¡Áö ´Ù¸¥ ½ÅÈ£ Àü´Þ ij½ºÄÉÀ̵带 È°¼ºÈÇÏ¿© ³»ÇÇ ¼¼Æ÷¿¡¼ VEGF ½ÅÈ£ Àü´ÞÀ» ¸Å°³ÇÏ´Â µ¥ Áß¿ä
...KDR¿¡ °áÇÕÇÏ´Â VEGF´Â Æ÷½ºÆÄƼµô À̳ë½ÃÅç 3- Å°³ªÁ¦ ¹× ¼¼Æ÷ »ýÁ¸À» ´ã´çÇÏ´Â ÁÖ¿ä °æ·Î ÀÎ Akt / ´Ü¹éÁú Å°³ªÁ¦ B¸¦ È°¼ºÈ ¼öÇà.
.. ¶ÇÇÑ VEGF´Â Æ÷½º Æ÷ ¸®ÆÄÁ¦ CγÀÇ °·ÂÇÑ È°¼ºÈ Á¦·Î¼ ¼¼Æ÷ ¿Ü ½ÅÈ£ Á¶Àý Å°³ªÁ¦ -1 ¹× -2 (ERK1 ¹× ERK2), ´Ü¹éÁú Å°³ªÁ¦ C ¹× ´Ü¹éÁú Å°³ªÁ¦ D °æ·ÎÀÇ È°¼ºÈ¸¦ ¸Å°³... ÀÌ È°¼ºÈ´Â Áõ°¡ µÈ À¯ÀüÀÚ ¹ßÇö, À¯»ç ºÐ¿ , ¼¼Æ÷ À̵¿ ¹× ÇÁ·Î ½ºÅ¸ »çÀÌŬ¸° »ý»êÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡..
. ³»ÇÇ ¼¼Æ÷¿¡¼ VEGF ½ÅÈ£ Àü´ÞÀÇ ¶Ç ´Ù¸¥ Áß¿äÇÑ ¸Å°³Ã¼´Â ¼¼Æ÷ ¿îµ¿ ¼º°ú ¾×ƾ ¼¼Æ÷ °ñ°Ý Á¶Á÷¿¡ Áß¿äÇÑ ¿ªÇÒÀ»ÇÏ´Â Src / ÃÊÁ¡ Á¢Âø Å°³ªÁ¦ (FAK) °æ·ÎÀÓ.... KDRÀº ³»ÇÇ ¼¼Æ÷¿¡¼ ÀÌ·¯ÇÑ ¸ðµç VEGF È¿°ú¿¡ Áß¿äÇÏÁö¸¸ NRP1Àº ƯÈ÷ ¼¼Æ÷ ¿îµ¿ ¼º°ú ÈÇÐ ÁÖ¼º À̵¿¿¡ Áß¿äÇÏÁö¸¸ ¼¼Æ÷ ºÐ¿¿¡´Â °ÅÀÇ ¿µÇâÀ» ¹ÌÄ¡Áö ¾ÊÀ½.
[[COVID19ÀÇ ¶Ç´Ù¸¥ ħ½À°æ·Î...Ä¡·áŸ°Ù ]] COVID19´Â º¸Åë ¼¼Æ÷¸·Ç¥¸éÀÇ ACE2¼ö¿ëü¸¦ ÅëÇØ ¼÷ÁÖ¼¼Æ÷ÀÇ Ä§½ÀÀ» ÀÏÀ¸Å°Áö¸¸ ½Å°æ ¼¼Æ÷³»·ÎÀÇ Ä§½ÀÀº spike protein S1ÀÌ ¼¼Æ÷¸·Ç¥¸é¿¡ °áÇյǾî ÀÖ´Â tyrosine kinase receptor·Î¼ °ø¿ë¼ö¿ëüÀÎ, neuropilin-1/VEGF-A¸¦ ³¬¾Æä¾î °áÇÕÇؼ pro-pain signaling systemÀ» Â÷´ÜÇÏ°í ½Å°æ¼¼Æ÷³»·Î ħ½À À¯¹ß(Á¶Á÷À̳ª ±â°üħ½À¼Õ»ó½Ã ±×°ÍÀ» ÀÚ°¢ÇÏ°Ô ÇÏ´Â ½ÅÈ£ÀÎ Åë°¢À» Â÷´Ü/ħ¹¬ÄÉ ÇÔ) ==>¹«Áõ»ó°¨¿°ÀÚ¸¦ ÅëÇÑ ¹ÙÀÌ·¯½ºÀüÆÄÈ®»ê À¯¹ß +Áø´Ü½Ã ÀÌ¹Ì Á¶Á÷À̳ª ±â°üµéÀÇ ¼Õ»óÀÌ ÁøÇàµÇ¾î ÀÖ´Â »óÅ°¡ µÊ [°ñ°üÀý¿° ÅëÁõÀÌ ½ÉÇÒ¼ö·Ï VEGF-A/neuropilin geneÀÇ È°¼ºµµ°¡ ³ô¾Æ¼ Ç÷û VEGF-A°¡ Áõ°¡ÇßÀ½!!]...anti-neuropilin-1 = anti-VEGF-A = mTOR inhibitor
=====
## PI3K/Akt/mTOR °æ·ÎÈ°¼ºÀº ¼¼Æ÷ÀÚ»ì/³ëÈ ¹× ¾Ï¼¼Æ÷Áõ½Ä-À̵¿-ºÐÈ ¹× Ç×¾ÏÁ¦³»¼ºÀÇ ¹ßÇö °ü·ÃµÊ : = PI3K/Akt/mTOR Â÷´ÜÁ¦µéÀº ´ë°³ SIRT1È°¼ºÈ¿°ú¸¦ ³ªÅ¸³»¸ç ±×¿Ü¿¡µµ ACE2¿Ü¿¡ COVID19ħ½À°æ·Î·Î¹àÇôÁø VEGF-A/neuropilin-1(NRP-1) °æ·Î ¾ïÁ¦Á¦ È¿°ú¸¦ ÇÔ²² ³ªÅ¸³¿À¸·Î½á °á±¹ COVID19 ħ½ÀÂ÷´Ü + ½Å°æÀμºÅëÁõ ¹× ¾Ï¼ºÅëÁõ Â÷´Ü + ¾ÏÁٱ⼼Æ÷Áõ½Ä ¹× ºÐÈ, À̵¿, ¼ºÀåÀ» ¾ïÁ¦+ Ç×¾ÏÁ¦¹Î°¨µµ Áõ°¡/¾àÁ¦³»¼º¹ß»ýȸÇÇ È¿°ú¸¦ ¾òÀ» ¼ö ÀÖÀ½ ((PI3K/Akt/mTOR inhibitors : Ä¿Å¥¹Î. ½Ç¸®¸¶¸°, ¼³Æ÷¶óÆÇ, EGCG,ÆÄÀÌÆ丰, Äõ¼¼Æ¾, È£³ëÅ°¿Ã, ·¹½ºº£¶óÆ®·Ñ))...
##**¾Æ¸£Å׹̽ôÑ(mTOR°æ·Î ¾ïÁ¦+VEGF¾ïÁ¦+ACE2¾ïÁ¦=COVID19ħ½ÀÂ÷´Ü+Ç×¾ÏÀÛ¿ë+Ç×±ÕG+ÀÛ¿ë/Ç×Áø±Õ) --³»ÇÇ ¼¼Æ÷¿¡¼ VEGF, NF-kB, VEGF-Flt-1, KDR/Flk-1 ¼ö¿ëüÀÇ ¹ßÇö ¼öÁØÀ» °¨¼Ò ½ÃÄÑ Ç×¾Ï È°¼ºÀ» ÃËÁø. **Artesunate -- artemisininÀÇ ¹ÝÇÕ¼º À¯µµÃ¼. HUVEC¿¡¼ ¿ë·® ÀÇÁ¸ÀûÀ¸·Î Ç÷°ü ½Å»ýÀ» ¾ïÁ¦ÇÏ¿© ¾Ï ¹ß»ýÀ» ¿¹¹æ. TGF-β1°ú IL-10ÀÇ ¼öÄ¡¸¦ °¨¼Ò½ÃÄÑ ¸é¿ª ¾ïÁ¦¸¦ °¨¼Ò½ÃÅ°°í ¾Ï°ú ½Î¿ì´Â Ç×¾Ï ¸é¿ªÀ» Á¦°ø. (Áß¿äÇÑ Ç×¾ÏÁ¦ ÀÏ °¡´É¼º)...HCQµµ µ¿ÀÏÇѱâÀüÀ¸·Î Ç×¾ÏÁ¦ ±â´É º¸À¯.
##Diseases Associated With mTOR Activation
Aging [15].....Cancer [16, 17]........Autoimmune disease.......Depression [18]......Diabetes [9]....Obesity [9].....Alzheimer’s [9]......Macular degeneration [9]....Kidney disease [9]....Epilepsy [9]...Autism (9, 19)....Chronic pain [9]....SLE [20]
##Inhibitors of mTOR
[mTOR pathway Â÷´Ü±âÀüÀÇ ¸é¿ª¾ïÁ¦Á¦µé] transplant rejection¾ïÁ¦/anticancer therapy.
Tacrolimus (Prograf, Advagraf)....Sirolimus (Rapamune)....Temsirolimus (Torisel)...Everolimus (Afinitor, Zortress)
The following strategies also inhibited the mTOR pathway, but the studies were mostly done in cells. Consult your doctor before implementing them and never used them to replace approved therapies.
[mTOR°æ·Î Â÷´Ü À¯¹ß=mTOR inhibitors]
^^Protein restriction [21, 22]...Calorie restriction [23]...Ketogenic Diets [24].....Intermittent Calorie Restriction [23].....Exercise (inhibits mTOR in the liver and fat cells, but activates it in the brain, muscle, and heart) [25, 26]....
^^remedy : Cortisol/Glucocorticoids [5]....Metformin [27]....NAC [28]....Resveratrol [29]....Aspirin [30]....Omega-3 [31]....Extra Virgin Olive Oil [32]....EGCG/Tea [33, 1, 34]....Curcumin [35, 1, 36].....R-Lipoic Acid [37]....Caffeine [38, 39, 1]....Fisetin (in fat cells) [40]....Apigenin [41].....Quercetin [42]....Genistein [1]....DIM [1]....Ursolic acid [43]....Alcohol [44]....Emodin (found in Fo-Ti, Rhubarb, Aloe) [45]....Andrographis/Andrographolide [46]....Pomegranate/Ellagic acid [47]....Reishi [48]....Milk thistle/Silymarin [49]....Oleanolic acid [50]...Anthocyanins/Grape Seed Extract [51]....Astragalus [52]....Rhodiola [53]....Carnosine [54]....Plumbagin(black walnut hull) [55]....Glucagon [56]....AICAR [27]
==========
[[PI3K-Akt-mTOR inhibitors, natural products]] **dec.neuropathic Pain via NRP-1 block
Name of compounds --Chemical classification::: Therapeutic uses
1>Gingerols --Predominated phenols of ginger oil :: Anticancer, antineuroinflammatory, antioxidant, anti-inflammatory, anti-cancer
2>**Curcumin --Flavonoid ::: Cardiovascular diseases, arthritis and inflammation, breast, gastric, colon, prostate cancers, melanoma, lymphoma, and leukemia
3>Diallyl Trisulfide --Organosulfur compound ::: Diabetes, cardiovascular disease, stimulate immune system, induce apoptosis in colon, gastric, prostate, and breast cancers
4>Emodin --Anthraquinone derivative ::: Several human cancers, neuroprotective, anti-viral
5>Ginsenoside RG3---Steroid glycosides and triterpene saponins ::: Numerous types of cancers- ovarian, lung, melanoma
6>D-Rhamnose β-hederin --Triterpenoid saponin :: :Cardiovascular disease, neuroprotective, antioxidant, anti-proliferative, neurodegenerative disease
7>Honokiol ---Neolignan biphenols :::Anti-thrombotic, anti-inflammatory, anti-oxidant, anti-cancer- multiple myeloma, lung, and colorectal
8>Matrine --Tetracyclic alkaloid ::: Anti-cancer, anti-inflammatory, anti-viral, anti-fibrotic, anti-arrhythmic, immunosuppressive
9>Parthenolide---Sesquiterpene lactone ::: Arthritis, fever, head ache, anticancer- prostate, skin, breast, bile duct, bowel, pancreas
10>Plumbagin---Naphthoquinone :::Anti-inflammatory, neuroprotective, hypolipidemic, anticancer, anti-atherosclerotic, anti-fungal, antibacterial
11>Triptolide---Diterpenoid triepoxide :::Arthritis, variety of cancers, anti-inflammatory, immunosuppressive, anti-cystogenesis
12>Wogonin---Flavone :::Anti-bacterial, antiviral, anti-oxidant, anti-inflammatory, anti-cancer
13>Thymoquinone --Benzoquinone of essential oil ::: Bronchial headache, asthma, dysentery, gastrointestinal problems
14>Andrographolide --Labdane diterpenoid ::: Upper respiratory tract infections, immunomodulatory, anti-cancer
15>**Resveratrol --Natural polyphenol with stilbene:::Anti-viral, anti-inflammatory, anti-leukemic, neuroprotective, chemoprotective, anti-oxidant
16>**Epigallocatechin-3-gallate --Polyphenol, catechin, ester of epigallocatechin and gallic acid :::Cardiovascular disease, anti-cancer, anti-obesity, skin protection from ionizing radiation
17>**Quercetin --Flavonoid:::Hay fever, diabetes, peptic ulcer, cataracts, asthma, schizophrenia, gout inflammation, viral infections, anti-cancer
18>Fistein --Flavonoid :::Anti-oxidant, anti-inflammatory, anti-cancer
19>Luteolin --Flavonoid ::: Anti-cancer, anti-oxidant, anti-inflammatory
20>Apigenin --Flavonoid ::: Anti-inflammatory, sedative, numerous cancers- prostate, melanoma, colon, and breast
21>**Indole-3-carbinol --Breakdown product of glucosinolate ::: Numerous cancer types- breast, colon, thyroid, gastric, prostate and mesothelioma
22>**Di-indolylmethane --Derived product from digestion of indole-3-carbinol ::: Anti-cancer
23>**Sulforaphane --Organosulfur compound with isothiocyanate group ::: Anti-cancer and anti-viral
24>Phenethyl isothiocyanate --Isothiocyanate derivative ::: Numerous cancers
25>Benzyl isothiocyanate --Isothiocyanate derivative ::: Anti-cancer
26>Dehydroglyasperin D --Prenyl flavonoid ::: Anti-obesity, aldose reductase inhibition, anti-cancer, anti-oxidant
27>Evodiamine --Quinolone alkaloid ::: Anti-nociceptive, anti-anoxia and vasorelaxant
28>Piceatannol --Natural analog of Resveratrol ::: Anti-cancer, anti-inflammatory, atherosclerosis, hypercholesterolemia, angiogenesis
29>Ellagic acid --Polyphenol ::: Anti-bacterial, anti-viral, anti-cancer
30>**Berberine via inhibition of ERK/mTOR signalling pathway ::: NAFLD
#CQ/HCQ artemisinin.artesunate == ACE2 inhibitor+VEGF inhibitor(Ç×¹ÙÀÌ·¯½º), autophagy inhibitor(Ç׳ëÈ),,anticancer effect(¾ÏÇ÷°ü½Å»ý¾ïÁ¦)#
#[[ºê·Î¸á¶óÀÎ COVIDF19¿¡¼ÀÇ ÀÛ¿ë±âÀü]] ¼÷ÁÖ¼¼Æ÷ ¼¼Æ÷¸·ÀÇ ACE2 ¹× TMPRSS2ÀÇ ¹ßÇöÀ» ¾ïÁ¦, VEGF-A/neuropilin-1 ¾ïÁ¦, COVID19 ½ºÆÄÀÌÅ© ´Ü¹é Àý´Ü/ºÐÇØ ==>COVID19 °¨¿°/¼÷ÁÖ¼¼Æ÷³»·ÎÀÇ Ä§½À ¾ïÁ¦(G+/G-Ç×±ÕÁ¦+Ç×¹ÙÀÌ·¯½ºÁ¦·Î ºÐ·ùµÊ) + Ç×¾ÏÁ¦(¾ÏÇ÷°ü½Å»ý¾ïÁ¦+¾Ï¼¼Æ÷ÀÚ¸êÀ¯µµ +NK¼¼Æ÷Áõ»ê) +Äݶó°Õ»ý»êÁõ°¡/ÁÖ¸§¹ß»ý¾ïÁ¦Á¦·Î¼ »ç¿ë °¡´É....COVID19´Â SARS-CoV-2 µ¿Á¾ »ï ÇÕü ¹ÙÀÌ·¯½º·Î¼ ½ºÆÄÀÌÅ© ´Ü¹éÁú (S1)Àº Ãʱâ ÁøÀÔÀ» À§ÇØ ¼÷ÁÖ ¼¼Æ÷ÀÇ ¼ö¿ëü ACE-2¿¡ °áÇÕÇÑ ´ÙÀ½¿¡´Â S2 ¸Å°³ ¹ÙÀÌ·¯½º-¼÷ÁÖ¼¼Æ÷°£ ¸· À¶ÇÕ ( 4 , 5 )À¸·Î À̾îÁü.. ÀÌ ¶§ S- ´Ü¹éÁúÀº ¼÷ÁÖ ¼¼Æ÷ Ç¥¸é¿¡ ¹ßÇöµÇ´Â TMPRSS2¿¡ ÀÇÇØ ´Ü¹éÁú ºÐÇØ ÇÁ¶óÀ̹ÖÀ» °ÅÄ¡°Ô µÇ´Âµ¥ ( 6 ). TMPRSS2´Â ¼¼¸° ÇÁ·ÎÅ×¾ÆÁ¦ È°¼ºÀ» °®´Â 70kDa À¯Çü II ¸· Ⱦ´Ü ´ç ´Ü¹éÁúÀÌ¸ç ¸¹Àº Á¶Á÷¼¼Æ÷µé¿¡¼ ¹ßÇöµÊ ( 7 )..... TMPRSS2´Â 9 °³ÀÇ ¾ÈÁ¤È ÀÌÈ²È °áÇÕ°ú 2 °³ÀÇ N- ±Û¸® Ä ºÎÀ§¸¦ °¡Áú °ÍÀ¸·Î ¿¹»óµÊ (UniProtKB-O15393)..... ¹Ù·Î ÀÌ ¼÷ÁÖ¼¼Æ÷ ¼¼Æ÷¸·ÀÇ TMPRSS2 ÇÁ¶óÀÌ¹Ö È°¼ºÀº ÀÎÇ÷翣ÀÚ A ¹ÙÀÌ·¯½º ( 8 , 9 ), SARS-CoV ( 10 ) ¹× SARS-CoV-2 ( 6 )¸¦ Æ÷ÇÔÇÑ ¸¹Àº ¹ÙÀÌ·¯½º °¨¿° ¾ïÁ¦¿¡ ÇʼöÀû ¿ä¼Ò°¡ µÊ.). ...BromelainÀº bFGF(¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ), VEGF(Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ), angiopoetin-1 ¹× 2, COX-2, MMP-9, AP-1 ¹× NF-κB¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ç÷°ü ½Å»ý ¼ºÀå ÀÎÀÚ, È¿¼Ò ¹× Àü»ç ÀÎÀÚ¸¦ ¾ïÁ¦Á¶ÀýÇÏ¿© ¾Ï¼¼Æ÷ÀÚ»ìÀ¯µµ(mTORÁõ°¡´Â ¾Ï¼¼Æ÷ ÀÚ»ì, ¾Ï¼¼Æ÷ÈÇÏ°í Àִ¼¼Æ÷µéÀÇ Á¤»ó¼¼Æ÷·ÎÀÇ º¹±Í¸¦ À¯µµ!!...¸á¶óÅä´Ñµµ µ¿ÀÏÇÑ ±âÀü.)[ƯÈ÷ Ç÷°ü½Å»ýÀÇ ÁÖ¿äÇ¥ÁöÀÚ´Â VEGF¿Í COX2!! ]...[AP-1/NFkB(ampk)-MMP9 °æ·Î´Â Á¾¾çħ½À°ü·Ã °æ·ÎÀÓ], Á¾¾çÁõ½ÄÀº Ç÷¼ÒÆÇÀÀÁýÁ¶°Ç¿¡¼ ÀϾ´Âµ¥...ºê·Î¸á¶óÀÎÅõ¿©½Ã Á¤»óÀÎÀÇ °æ¿ì, Ç÷¼ÒÆÇÀÌ ¾à°£ ÀúÇϵǴ ¼Ò°ßµµ º¼ ¼ö ÀÖÀ½
--------
[Ç×Áø±ÕÁ¦·Î¼ÀÇ phytochemicals : Áø±Õ =¹«Á»±Õ, ĵð´Ù, Å©¸³ÅäÄÚÄí½º] ¾ÈÅä½Ã¾È º£¸£º£¸°/ ºê·Î¸á¸° EGCG ½Ç¸®¸¶¸° ¼³Æ÷¶óÆÇ Ä¿Å¥¹Î Äõ¼¼Æ¾ ÆÄÀÌÆ丰 ÇÁ·ÎÆú¸®½º/¸¶´Ã .....
[Ç×Áø±Õ, Ç×±ÕÁ¦·Î¼ÀÇ A.annua, AZT]..ART¿Í A.annua´Â C. albicans ¹× Å©¸³ÅäÄÚÄí½º, G+±Õ, G-Áß Salmo¿¡´Â ¸ðµÎ Ç×±ÕÀÛ¿ë º¸ÀÓ, ART¿¡ ¾Èµè´Â E.coli¿¡µµ A.annua´Â È¿°ú
==µÎ°³Ãµ°ñ¿ä¹ý, CRANIOSACRAL THERAPY.====
@@BNT162b2 mRNA Covid-19 ¹é½ÅÀÇ ¾ÈÀü¼º ¹× È¿´É NEJM2020-12.
ÃÑ43448¸í(À§¾àF21733.¹é½ÅV21720) -->RT-PCR(+)À¯Áõ»óÀÚ168(F162, V6) : 95%protection.....RT-PCR°Ë»ç sample size(0.38%) ½Å·Úµµ ¹®Á¦ .....¹ÙÀÌ·¯½ºÀ¯ÀüÀÚ·Î ¸¸µå´Â »ý¹é½Å=¹ÙÀÌ·¯½º ±× ÀÚüÀ̱⿡ ¾ß±âµÇ´Â »ç¸Á¿øÀÎÀÎ CSS-DIC ÇÕº´Áõ ¹ß»ýµÇ´Â ¹®Á¦......normalFlora°ø»ý/ħ½ÀºÎÀ§´Â Á¡¸·Àε¥, »ï°¢±Ù³» Á¢Á¾À¸·Î ÀÎÇÑ ¹«¹æºñ»óÅ·ΠÇ÷°ü³»·Î ÁøÀÔ½ÃÄѹö¸®´Â ¹Ù Á¢Á¾·çÆ®ÀÇ ¹®Á¦
=======
===È÷µå·Ï½ÃŬ·Î·ÎÄý Äڷγª19 »ç¸Á°¨¼ÒÁ¶±â Åõ¿©, ¸é¹Ð ½ÉÀå ¸ð´ÏÅ͸µ »ç¸Á·ü À§Çèºñ 66% °¨¼Ò ===[ÀÇÇнŹ®·ÀÏ°£º¸»ç=±èÀÚ¿¬ ±âÀÚ...2020.07.06]
ÃÖ±Ù ¼¼°èÀûÀ¸·Î Äڷγª19¿¡ È÷µå·Ï½ÃŬ·Î·ÎÄýÀÇ ÀÓ»ó½ÃÇèÀÌ Áߴܵǰí ÀÖ´Â °¡¿îµ¥, È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ ½ÉÀå °ü·Ã ºÎÀÛ¿ë ¾øÀÌ Äڷγª19 ÀÔ¿ø ȯÀÚÀÇ »ç¸ÁÀ» »ó´çÈ÷ °¨¼Ò½Ãų ¼ö ÀÖ´Ù´Â ¿¬±¸ °á°ú°¡ ³ª¿Ô´Ù.
¹Ì±¹ Ç Æ÷µå Çコ ½Ã½ºÅÛ ¿¬±¸ÁøÀº ´ë±Ô¸ð ȸ°íÀû ºÐ¼® ¿¬±¸ °á°ú ÀÌ°°ÀÌ ³ªÅ¸³µ´Ù°í ±¹Á¦ °¨¿°Áúȯ Àú³ÎÀ» ÅëÇØ ¹ßÇ¥Çß´Ù.
±×µ¿¾È È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ È¿°ú¸¦ º¸ÀÌÁö ¸øÇÑ ±âÁ¸ ¿¬±¸¿Í Â÷ÀÌÁ¡À¸·Î ¿¬±¸ÁøÀº Á¶±â¿¡ Ä¡·á¸¦ ½ÃÀÛÇß°í ¸é¹ÐÈ÷ ½ÉÀåÀ» ¸ð´ÏÅ͸µÇßÀ¸¸ç ´Ù¸¥ ¿¬±¸¿Í ¿ë·®¿¡ Â÷À̵µ ÀÖ´Ù°í ¼³¸íÇß´Ù.
À̹ø ¿¬±¸´Â Áö³ 3¿ù 10ÀϺÎÅÍ 5¿ù 2ÀÏ »çÀÌ Ç Æ÷µå Çコ ½Ã½ºÅÛ¿¡ ÀÔ¿øÇÑ È®ÁøÀÚ ÃÑ 2541¸íÀ» ´ë»óÀ¸·Î Áß°£ 28.5ÀÏ µ¿¾È ÃßÀûµÆÀ¸¸ç ȯÀÚÀÇ Æò±Õ ¿¬·ÉÀº 64¼¼¿´°í 56%°¡ ÈæÀÎÀ̾ú´Ù.
¿¬±¸¿¡¼ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á ȯÀÚµéÀÇ 82%°¡ ÀÔ¿ø 24½Ã°£ À̳», 91%°¡ 48½Ã°£ À̳» È÷µå·Ï½ÃŬ·Î·ÎÄýÀ» Åõ¿©¹Þ¾Ò´Ù.
È÷µå·Ï½ÃŬ·Î·ÎÄýÀÇ ¿ë·®Àº 1ÀÏ° ÇÏ·ç 2ȸ 400mg µÎ º¹¿å·®À¸·Î, 2~5ÀÏ° ÇÏ·ç 2ȸ 200mgÀ» Åõ¿©Çß´Ù.
¿¬±¸ÁøÀÌ È¯ÀÚµéÀÇ ½ÉÀå »óŸ¦ ÀÏÁ¤ÇÏ°Ô ¸ð´ÏÅ͸µÇÑ ¸¸Å ´©±¸µµ ÁßÁõ ½ÉÀå ºÎÀÛ¿ëÀ» °ÞÁö ¾Ê¾Ò´Ù.
ƯÈ÷ ½ÉÀå À§Çè ¿äÀÎÀÌ ÀûÀº ÁßÁõ ȯÀÚÀÇ °æ¿ì¿£ È÷µå·Ï½ÃŬ·Î·ÎÄý°ú ¾ÆÁö½º·Î¸¶À̽ÅÀ» º´¿ëÅõ¿©Çß´Ù. º´¿ëÇÑ ¾ÆÁö½º·Î¸¶À̽ÅÀº 1ÀÏ° ÇÏ·ç 1ȸ 500mgºÎÅÍ ½ÃÀÛÇØ ´ÙÀ½ 4ÀÏ µ¿¾È ÇÏ·ç 1ȸ 250mgÀ» ÁÖ¾ú´Ù.
±× °á°ú ÀüüÀûÀ¸·Î ¿ø³» »ç¸Á·üÀº 18.1%·Î ³ªÅ¸³ °¡¿îµ¥ Ä¡·áº° »ç¸Á·üÀº È÷µå·Ï½ÃŬ·Î·ÎÄý ´Üµ¶ Ä¡·á ȯÀÚ Áß 13.5%, È÷µå·Ï½ÃŬ·Î·ÎÄý°ú ¾ÆÁö½º·Î¸¶À̽Šº´¿ë ȯÀÚ Áß 20.1%, ¾ÆÁö½º·Î¸¶À̽Š´Üµ¶ Ä¡·á ȯÀÚ Áß 22.4%À¸·Î ³ªÅ¸³µ°í µÎ Ä¡·áÁ¦ Áß ¹«¾ùµµ ¹ÞÁö ¾ÊÀº ȯÀÚ´Â 26.4%·Î ³ª¿Ô´Ù. »ç¸ÁÀÇ 88%´Â È£Èí ºÎÀüÀ¸·Î ÀϾ°í ´ÙÇü ½É½Ç ºó¸ÆÀº ¹ß»ýÇÏÁö ¾Ê¾Ò´Ù.
ÀÌ¿¡ µû¶ó ¿¬±¸ÁøÀº È÷µå·Ï½ÃŬ·Î·ÎÄýÀ̳ª ¾ÆÁö½º·Î¸¶À̽ŠÁß ¾Æ¹«°Íµµ ¹ÞÁö ¾ÊÀº ȯÀÚ¿¡ ºñÇØ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á´Â »ç¸Á·ü À§Çèºñ¸¦ 66% °¨¼Ò½ÃÄ×°í µÎ º´¿ëÀº 71% ÁÙ¿´´Ù°í °á·ÐÁö¾ú´Ù.
ƯÈ÷ ¿¬±¸ÁøÀº È÷µå·Ï½ÃŬ·Î·ÎÄýÀÌ È¿°ú°¡ ÀÖÀ¸·Á¸é ÁßÁõ ¸é¿ª ¹ÝÀÀÀÌ ÀϾ±â ÀÌÀü¿¡ Åõ¿©ÇÒ ÇÊ¿ä°¡ ÀÖ´Ù°í ÆòÇß´Ù.
´Ü °ü·Ã ³íÆò¿¡¼´Â È÷µå·Ï½ÃŬ·Î·ÎÄýÀ» ¹ÞÀº ȯÀÚµé °¡¿îµ¥ ½ºÅ×·ÎÀÌµå µ¿½Ã Åõ¿© ȯÀÚ°¡ È÷µå·Ï½ÃŬ·Î·ÎÄý Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº ȯÀÚ¿¡ ºñÇØ 2¹è ÀÌ»óÀ̾ú´Ù¸ç, ÀÌ´Â ÃÖ±Ù ¹ß°ßµÈ µ¦»ç¸ÞŸ¼ÕÀÇ »ç¸Á °¨¼Ò È¿°ú¿Í °ü·Ã ÀÖÀ» ¼ö ÀÖ´Ù´Â ÁöÀûµµ ³ª¿Ô´Ù.((±èÀÚ¿¬ ±âÀÚ nature@bosa.co.kr)) |